ATE346858T1 - Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph - Google Patents

Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph

Info

Publication number: ATE346858T1
Authority: AT; Austria
Prior art keywords: antibodies; cleaning; low; hydrophobic interaction; interaction chromatography
Prior art date: 1995-04-20

Application number

AT96912575T

Other languages

English (en)

Inventor

Ernst H Rinderknecht

Gerardo A Zapata

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-20

Filing date

1996-04-05

Publication date

2006-12-15

1996-04-05 Application filed by Genentech Inc filed Critical Genentech Inc

2006-12-15 Application granted granted Critical

2006-12-15 Publication of ATE346858T1 publication Critical patent/ATE346858T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT96912575T 1995-04-20 1996-04-05 Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph ATE346858T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/425,763 US5641870A (en)	1995-04-20	1995-04-20	Low pH hydrophobic interaction chromatography for antibody purification

Publications (1)

Publication Number	Publication Date
ATE346858T1 true ATE346858T1 (de)	2006-12-15

Family

ID=23687930

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06022818T ATE510854T1 (de)	1995-04-20	1996-04-05	Lineares, schweres antikörperkettenfragment vh- ch1-vh-ch1
AT96912575T ATE346858T1 (de)	1995-04-20	1996-04-05	Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT06022818T ATE510854T1 (de)	1995-04-20	1996-04-05	Lineares, schweres antikörperkettenfragment vh- ch1-vh-ch1

Country Status (16)

Country	Link
US (5)	US5641870A (de)
EP (2)	EP1752465B1 (de)
JP (3)	JP4042868B2 (de)
AT (2)	ATE510854T1 (de)
AU (1)	AU721736B2 (de)
CA (1)	CA2214633C (de)
DE (1)	DE69636733T2 (de)
DK (2)	DK0821695T3 (de)
ES (2)	ES2365929T3 (de)
HK (1)	HK1099310A1 (de)
IL (1)	IL117942A (de)
MX (1)	MX9707909A (de)
NZ (2)	NZ306718A (de)
PT (1)	PT821695E (de)
WO (1)	WO1996033208A1 (de)
ZA (1)	ZA962885B (de)

Families Citing this family (1170)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG43125A1 (en) *	1993-10-27	1997-10-17	Molex Inc	Shunted electrical connector
US5641870A (en) *	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US20040121415A1 (en) *	1996-12-10	2004-06-24	King David John	Monovalent antibody fragments
US8088386B2 (en)	1998-03-20	2012-01-03	Genentech, Inc.	Treatment of complement-associated disorders
AU2003200709B2 (en) *	1998-05-06	2006-06-29	Genentech, Inc.	Protein purification
SI1308456T1 (sl) *	1998-05-06	2008-02-29	Genentech Inc	Ciscenje protiteles z ionsko izmenjevalno kromatografijo
CA2329829C (en)	1998-05-06	2012-10-16	Genentech, Inc.	Protein purification by ion exchange chromatography
SI2283866T1 (sl)	1999-06-25	2015-07-31	Genentech, Inc.	POSTOPKI ZA ZDRAVLJENJE Z UPORABO KONJUGATOV MAYNTASINOIDNIH PROTITELES PROTI ERbB
DK2283866T3 (en)	1999-06-25	2015-05-18	Genentech Inc	METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
JP2001066308A (ja) *	1999-07-29	2001-03-16	Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh	ＩｇＧ抗体の不可逆的損傷の検出
WO2001035735A1 (en) *	1999-11-19	2001-05-25	Hematech, Llc	Production of ungulates, preferably bovines that produce human immunoglobulins
US7820878B2 (en) *	1999-11-19	2010-10-26	Kyowa Hakko Kirin Co., Ltd.	Production of ungulates, preferably bovines that produce human immunoglobulins
US7414170B2 (en) *	1999-11-19	2008-08-19	Kirin Beer Kabushiki Kaisha	Transgenic bovines capable of human antibody production
US7074983B2 (en) *	1999-11-19	2006-07-11	Kirin Beer Kabushiki Kaisha	Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US20030023043A1 (en) *	2000-03-02	2003-01-30	Kazuhisa Uchida	Method of separating and purifying protein
EP1260518A4 (de) *	2000-03-02	2004-12-08	Kyowa Hakko Kogyo Kk	Verfahren zur trennung und reinigung von protein
IL151853A0 (en)	2000-04-11	2003-04-10	Genentech Inc	Multivalent antibodies and uses therefor
CA2411102A1 (en)	2000-06-20	2001-12-27	Idec Pharmaceutical Corporation	Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US6984522B2 (en)	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
WO2002030954A1 (fr) *	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Procede de purification d'un anticorps
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
DE60139944D1 (de)	2000-10-12	2009-10-29	Genentech Inc	Niederviskose konzentrierte proteinformulierungen
US6979556B2 (en) *	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20020159996A1 (en)	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK2000545T3 (da)	2001-06-20	2011-11-28	Genentech Inc	Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
CA2454731C (en)	2001-08-27	2010-11-02	Genentech, Inc.	A system for antibody expression and assembly
US20040235068A1 (en) *	2001-09-05	2004-11-25	Levinson Arthur D.	Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
EP2151244A1 (de)	2001-09-18	2010-02-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20050123925A1 (en)	2002-11-15	2005-06-09	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20030228319A1 (en)	2002-04-16	2003-12-11	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
JP2005525095A (ja)	2002-01-02	2005-08-25	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
EP1501856B1 (de)	2002-04-10	2012-12-19	Genentech, Inc.	Anti-her2-antikörpervarianten
WO2005117986A2 (en)	2004-06-01	2005-12-15	Genentech, Inc.	Antibody drug conjugates and methods
EP1532453B1 (de) *	2002-05-31	2013-08-21	Genetic Technologies Limited	Maternale antikörper als marker für fötale zellen zur identifizierung und anreicherung fötaler zellen aus maternalem blut
EP2305710A3 (de)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetische Antikörperphagenbibliotheken
ES2392525T3 (es)	2002-07-15	2012-12-11	F. Hoffmann-La Roche Ag	Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
CA2496925A1 (en) *	2002-08-29	2004-03-11	Genentech, Inc.	Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
SI1539798T1 (sl) *	2002-09-06	2011-03-31	Genentech Inc	Postopek za proteinsko ekstrakcijo
US9453251B2 (en)	2002-10-08	2016-09-27	Pfenex Inc.	Expression of mammalian proteins in Pseudomonas fluorescens
AU2003286493A1 (en) *	2002-10-18	2004-05-04	Abgenix, Inc.	System and method for cleaving antibodies
JP2006505291A (ja) *	2002-11-08	2006-02-16	ヘマテック，エルエルシー	プリオンタンパク質活性が低減されたトランスジェニック有蹄動物及びその用途
PL377653A1 (pl)	2003-01-09	2006-02-06	Genentech, Inc.	Oczyszczanie polipeptydów
US8394582B2 (en) *	2003-03-05	2013-03-12	Genetic Technologies, Inc	Identification of fetal DNA and fetal cell markers in maternal plasma or serum
EP1614693A4 (de) *	2003-03-31	2006-07-19	Kirin Brewery	Reinigung eines humanen monoklonalen antikörpers und humanen polyklonalen antikörpers
DK2335725T3 (en)	2003-04-04	2017-01-23	Genentech Inc	Highly concentrated antibody and protein formulations
UA91961C2 (ru)	2003-04-09	2010-09-27	Дженентек, Инк.	Лечение аутоимунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
KR20180014881A (ko)	2003-05-30	2018-02-09	제넨테크, 인크.	항-ｖｅｇｆ 항체를 사용한 치료
CA2526080A1 (en) *	2003-05-30	2005-01-06	Genentech, Inc.	Polypeptides that bind an anti-tissue factor antibody and uses thereof
WO2005000351A2 (en)	2003-06-05	2005-01-06	Genentech, Inc.	Combination therapy for b cell disorders
JP5068072B2 (ja) *	2003-06-27	2012-11-07	バイオジェン・アイデック・エムエイ・インコーポレイテッド	連結ペプチドを含む改変された結合分子
PL1641822T3 (pl)	2003-07-08	2013-10-31	Genentech Inc	Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
WO2005037869A2 (en) *	2003-10-15	2005-04-28	Applera Corporation	Method of reducing leachate from protein a affinity media
ATE462716T1 (de) *	2003-10-24	2010-04-15	Amgen Inc	Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
NZ547633A (en)	2003-11-06	2010-08-27	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
US20050214805A1 (en) *	2003-11-10	2005-09-29	Q-Rna, Inc.	Methods of detection employing immuno-Q-Amp technology
SI2295073T1 (sl)	2003-11-17	2014-07-31	Genentech, Inc.	Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
US20060122784A1 (en) *	2004-12-03	2006-06-08	Ishikawa Muriel Y	System and method for augmenting a humoral immune response
US20060095211A1 (en) *	2003-12-05	2006-05-04	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	System and method for modulating a cell mediated immune response
US20060047436A1 (en) *	2004-08-25	2006-03-02	Ishikawa Muriel Y	System and method for magnifying an immune response
US20060047437A1 (en) *	2004-08-25	2006-03-02	Ishikawa Muriel Y	System and method for heightening an immune response
US20060122783A1 (en) *	2004-08-24	2006-06-08	Ishikawa Muriel Y	System and method for heightening a humoral immune response
US20060116824A1 (en) *	2004-12-01	2006-06-01	Ishikawa Muriel Y	System and method for modulating a humoral immune response
US20060047434A1 (en) *	2004-08-24	2006-03-02	Ishikawa Muriel Y	System and method related to improving an immune system
US20060047435A1 (en) *	2004-08-24	2006-03-02	Ishikawa Muriel Y	System and method related to augmenting an immune system
US20060182742A1 (en) *	2004-08-24	2006-08-17	Ishikawa Muriel Y	System and method for magnifying a humoral immune response
EP1715948B1 (de) *	2004-01-20	2016-11-23	Pall Corporation	Chromatographisches material zur absorption von proteinen bei physiologischer ionenstärke
WO2005087812A1 (en) *	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP1740615B1 (de)	2004-03-31	2014-11-05	Genentech, Inc.	Humanisierte anti-tgf-beta-antikörper
US20150017671A1 (en)	2004-04-16	2015-01-15	Yaping Shou	Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20060002930A1 (en) *	2004-04-16	2006-01-05	Genentech, Inc.	Treatment of disorders
JP2007532681A (ja) *	2004-04-16	2007-11-15	ジェネンテック・インコーポレーテッド	Ｂ細胞の枯渇を増大させる方法
CN101014715A (zh) *	2004-04-22	2007-08-08	麒麟麦酒株式会社	转基因动物及其用途
AU2005249566B2 (en)	2004-06-04	2010-11-11	Genentech, Inc.	Method for treating multiple sclerosis
US8604185B2 (en)	2004-07-20	2013-12-10	Genentech, Inc.	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2005269716B2 (en) *	2004-07-20	2011-01-27	Genentech, Inc.	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CN101031655A (zh)	2004-07-26	2007-09-05	陶氏环球技术公司	通过株工程改进蛋白表达的方法
US20070207492A1 (en) *	2004-08-24	2007-09-06	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems to adjust a humoral immune response
US20070265818A1 (en) *	2004-08-24	2007-11-15	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems for heightening cell-mediated immune response
US20060047439A1 (en) *	2004-08-24	2006-03-02	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	System and method for improving a humoral immune response
US20070265819A1 (en) *	2004-08-24	2007-11-15	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems for improving cell-mediated immune response
US20070265817A1 (en) *	2004-08-24	2007-11-15	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational systems and methods relating to fortifying an immune system
US20070288173A1 (en) *	2004-08-24	2007-12-13	Searete Llc, A Limited Liability Corporation Of The State Of Delware	Computational methods and systems to reinforce a humoral immune response
US20070265788A1 (en) *	2004-08-24	2007-11-15	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems for augmenting cell-mediated immune response
US20070265787A1 (en) *	2004-08-24	2007-11-15	Searete Llc,A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems for magnifying cell-mediated immune response
US20070198196A1 (en) *	2004-08-24	2007-08-23	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational systems and methods relating to ameliorating an immune system
US20070196362A1 (en) *	2004-08-24	2007-08-23	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems to bolster an immune response
US20060051347A1 (en)	2004-09-09	2006-03-09	Winter Charles M	Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
NZ590132A (en) *	2004-10-21	2012-03-30	Genentech Inc	Dosage regime for treating intraocular neovascular diseases with VEGF
WO2006074399A2 (en) *	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
DK1841793T3 (da)	2005-01-07	2010-07-19	Diadexus Inc	Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
KR20150083139A (ko)	2005-01-21	2015-07-16	제넨테크, 인크.	Ｈｅｒ 항체의 고정 용량 투여법
WO2006091693A2 (en)	2005-02-23	2006-08-31	Genentech, Inc.	Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TW200642695A (en) *	2005-03-08	2006-12-16	Genentech Inc	Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
WO2006099308A2 (en)	2005-03-11	2006-09-21	Wyeth	A method of weak partitioning chromatography
AU2006235695B2 (en)	2005-04-09	2011-10-13	Fusion Antibodies Limited	Cathepsin S antibody
EP1871163A2 (de)	2005-06-06	2008-01-02	Genentech, Inc.	Transgene tiermodelle und deren verwendung zur gencharakterisierung
EP1917020B1 (de)	2005-07-07	2016-05-25	Seattle Genetics, Inc.	Monomethylvalin-verbindungen mit phenylalanin-seitenketten-modifikationen am c-terminus
US8871720B2 (en) *	2005-07-07	2014-10-28	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
WO2007021423A2 (en)	2005-08-15	2007-02-22	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
EP2500357A3 (de)	2005-08-19	2012-10-24	Abbott Laboratories	Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
EP2520588A1 (de)	2005-08-19	2012-11-07	Abbott Laboratories	Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US9119828B2 (en) *	2005-09-23	2015-09-01	The United States Of America As Represented By The Secretary Of The Army	Antibodies with simultaneous subsite specificities to protein and lipid epitopes
US7422899B2 (en) *	2005-10-05	2008-09-09	Biogen Idec Ma Inc.	Antibodies to the human prolactin receptor
US9850311B2 (en)	2005-10-31	2017-12-26	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
WO2007056411A2 (en) *	2005-11-08	2007-05-18	Genentech, Inc.	Method of producing pan-specific antibodies
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
JP2009516514A (ja)	2005-11-21	2009-04-23	ジェネンテック・インコーポレーテッド	新規遺伝子破壊、それらに関する組成物および方法
CN105859886A (zh)	2005-12-02	2016-08-17	健泰科生物技术公司	牵涉与il-22和il-22r结合的抗体的组合物和方法
CN103396485B (zh)	2005-12-15	2016-08-10	健泰科生物技术公司	靶向多聚泛蛋白的方法和组合物
US7625759B2 (en) *	2005-12-19	2009-12-01	Genentech, Inc.	Method for using BOC/CDO to modulate hedgehog signaling
DK1973950T3 (en)	2006-01-05	2014-12-15	Genentech Inc	ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
JP2009527227A (ja)	2006-02-17	2009-07-30	ジェネンテック・インコーポレーテッド	遺伝子破壊、それに関連する組成物および方法
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
UA100969C2 (uk)	2006-03-21	2013-02-25	Дженентек, Інк.	Антитіло, яке специфічно зв'язує людський альфа5бета1 (alpha5beta1)
RU2008141912A (ru)	2006-03-23	2010-04-27	Новартис АГ (CH)	Противоопухолевые лекарства на основе антител к клеточным антигенам
EP2007428A2 (de)	2006-04-05	2008-12-31	Genentech, Inc.	Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
BRPI0709726A2 (pt)	2006-04-05	2011-07-26	Abbott Biotechnology Ltd.	purificaÇço de anticorpo
DE102006017701A1 (de) *	2006-04-15	2007-10-25	Degussa Gmbh	Silicium-Titan-Mischoxidpulver, Dispersion hiervon und daraus hergestellter titanhaltiger Zeolith
CA2649387A1 (en)	2006-04-19	2008-03-27	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
US20090142259A1 (en) *	2006-05-12	2009-06-04	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
MX2008015132A (es)	2006-05-30	2008-12-10	Genentech Inc	Anticuerpos e inmunoconjugados y sus usos.
EP2049570B1 (de) *	2006-06-01	2016-08-10	President and Fellows of Harvard College	Reinigung von bivalent aktiven antikörpern, mit verwendung von einem nicht-chromatographischen verfahren
US8874380B2 (en)	2010-12-09	2014-10-28	Rutgers, The State University Of New Jersey	Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2008009545A1 (en)	2006-06-30	2008-01-24	Novo Nordisk A/S	Anti-nkg2a antibodies and uses thereof
ES2612383T3 (es)	2006-07-19	2017-05-16	The Trustees Of The University Of Pennsylvania	WSX-1/IL-27 como una diana para respuestas antiinflamatorias
CA2660286A1 (en)	2006-08-09	2008-02-21	Homestead Clinical Corporation	Organ-specific proteins and methods of their use
EP2061900A2 (de)	2006-08-25	2009-05-27	Oncotherapy Science, Inc.	Prognostische marker und therapeutische ziele bei lungenkrebs
ES2399075T3 (es) *	2006-08-30	2013-03-25	Genentech, Inc.	Anticuerpos multiespecíficos
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
EP2527425A1 (de)	2006-09-13	2012-11-28	Abbott Laboratories	Verbesserungen an Zellkulturen
WO2011008990A1 (en)	2009-07-15	2011-01-20	Prometheus Laboratories Inc.	Drug selection for gastric cancer therapy using antibody-based arrays
US20080076139A1 (en)	2006-09-21	2008-03-27	Sharat Singh	Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
ES2557953T3 (es)	2006-09-29	2016-01-29	Oncomed Pharmaceuticals, Inc.	Composiciones y métodos para diagnosticar y tratar cáncer
KR20090078349A (ko) *	2006-10-12	2009-07-17	제넨테크, 인크.	림포톡신-알파에 대한 항체
PL2845866T3 (pl)	2006-10-27	2017-10-31	Genentech Inc	Przeciwciała i immunokoniugaty oraz ich zastosowanie
TWI442965B (zh) *	2006-11-01	2014-07-01	Biogen Idec Inc	使用低ｐＨ及二價陽離子分離生物巨分子的方法
US20080108147A1 (en) *	2006-11-03	2008-05-08	Tie Wei	Reduction of non-specific binding in immunoassays
MX2009005466A (es)	2006-11-22	2009-08-17	Adnexus A Bristol Myers Sqibb	Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
AU2007325283B2 (en)	2006-11-27	2012-08-30	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
US20090186034A1 (en) *	2006-12-19	2009-07-23	Genetech, Inc.	Gene expression markers for inflammatory bowel disease
US20080171344A1 (en) *	2006-12-22	2008-07-17	Kapsner Kenneth P	Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
US20090068110A1 (en) *	2006-12-22	2009-03-12	Genentech, Inc.	Antibodies to insulin-like growth factor receptor
EP2120915B1 (de)	2007-01-22	2011-09-28	Genentech, Inc.	Abscheidung von polyelektrolyten und reinigung von antikörpern
WO2008092002A2 (en)	2007-01-24	2008-07-31	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing pancreatic cancer
WO2008091222A1 (en) *	2007-01-26	2008-07-31	Bioinvent International Ab	Dll4 signaling inhibitors and uses thereof
WO2008100805A2 (en)	2007-02-09	2008-08-21	Genentech, Inc.	Anti-robo4 antibodies and uses therefor
WO2008100578A2 (en) *	2007-02-14	2008-08-21	Amgen Inc.	Method of isolating antibodies by precipitation
KR101508397B1 (ko)	2007-02-22	2015-04-08	제넨테크, 인크.	염증성 장 질환의 검출 방법
CN101680897B (zh)	2007-03-02	2013-11-13	健泰科生物技术公司	基于低her3表达预测对her二聚化抑制剂的响应
JP5284290B2 (ja)	2007-03-14	2013-09-11	リゴサイトファーマスーティカルズ，インコーポレイテッド	ウイルス様粒子の精製
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US9580719B2 (en)	2007-04-27	2017-02-28	Pfenex, Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en)	2007-04-27	2016-07-19	Pfenex Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008144029A1 (en)	2007-05-14	2008-11-27	The University Of Chicago	Antibody-light fusion products for cancer therapeutics
WO2008154249A2 (en)	2007-06-08	2008-12-18	Genentech, Inc.	Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2691378A1 (en)	2007-07-02	2009-01-08	Oncomed Pharmaceuticals, Inc.	Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer
PL2474557T3 (pl)	2007-07-16	2015-02-27	Genentech Inc	Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
KR101559595B1 (ko)	2007-07-16	2015-10-12	제넨테크, 인크.	인간화 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
AU2008282218A1 (en) *	2007-07-31	2009-02-05	Medimmune, Llc	Multispecific epitope binding proteins and uses thereof
CA3128656A1 (en)	2007-08-22	2009-02-26	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
RU2010111116A (ru)	2007-08-24	2011-09-27	Онкотерапи Сайенс, Инк. (Jp)	Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы
JP2010536844A (ja)	2007-08-24	2010-12-02	オンコセラピー・サイエンス株式会社	癌の治療標的及び診断マーカーとしてのｄｋｋ１癌遺伝子
KR20100075857A (ko)	2007-08-24	2010-07-05	온코세라피 사이언스 가부시키가이샤	폐암의 치료 및 진단의 표적유전자인 ｅｂｉ３，ｄｌｘ５，ｎｐｔｘ１ 및 ｃｄｋｎ
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
EP3127921A1 (de)	2007-09-26	2017-02-08	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
CA2699601A1 (en)	2007-10-02	2009-04-09	Genentech, Inc.	Nlrr-1 antagonists and uses thereof
US20090149638A1 (en) *	2007-10-03	2009-06-11	Ley Arthur C	Systems and methods for purifying proteins
DK2233149T3 (en)	2007-10-16	2016-05-17	Zymogenetics Inc	COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
RU2498991C2 (ru)	2007-10-30	2013-11-20	Дженентек, Инк.	Очистка антител с помощью катионообменной хроматографии
ES2663077T3 (es)	2007-11-02	2018-04-11	Novartis Ag	Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
DK2514436T3 (en)	2007-11-07	2018-03-12	Genentech Inc	IL-22 FOR USE IN TREATMENT OF MICROBIAL DISEASES
WO2010135521A2 (en)	2009-05-20	2010-11-25	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
US8057796B2 (en) *	2007-11-12	2011-11-15	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) *	2007-11-12	2011-02-10	Theraclone Sciences Inc.	Compositions and methods for the therapy and diagnosis of influenza
AU2008334095A1 (en)	2007-11-29	2009-06-11	Genentech, Inc.	Gene expression markers for inflammatory bowel disease
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
GB0723797D0 (en)	2007-12-05	2008-01-16	Immunosolv Ltd	Method
CA2708854C (en)	2007-12-14	2017-11-28	Novo Nordisk A/S	Antibodies against human nkg2d and uses thereof
AU2008352942B2 (en)	2007-12-19	2013-09-12	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
AR070141A1 (es) *	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
RU2010133892A (ru)	2008-01-24	2012-02-27	Ново Нордиск А/С (DK)	Гуманизированные моноклональные антитела против человеческого nkg2a
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
IL295449A (en)	2008-01-31	2022-10-01	Genentech Inc	and fusion antibody-drug-cd79b engineered antibodies cysteine-
CN102007145A (zh)	2008-02-14	2011-04-06	百时美施贵宝公司	基于结合egfr的工程化蛋白质的靶向治疗剂
DK2602623T3 (en)	2008-02-25	2015-11-09	Nestec Sa	METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
US20110092452A1 (en) *	2008-03-05	2011-04-21	The Regents Of The University Of Michigan	Compositions and methods for diagnosing and treating pancreatic cancer
EP2257571B1 (de)	2008-03-10	2015-03-04	Theraclone Sciences, Inc.	Zusammensetzungen und methoden zur therapie und diagnose von cytomegalovirus-infektionen
US10000568B2 (en)	2008-04-10	2018-06-19	Cell Signaling Technology, Inc.	Compositions and methods for detecting EGFR in cancer
MX2010011206A (es) *	2008-04-16	2010-11-12	Biogen Idec Inc	Metodo para aislar biomacromoleculas usando glicol de polialquileno y metales de transicion.
JP5646457B2 (ja)	2008-04-29	2014-12-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
US8680025B2 (en) *	2008-05-09	2014-03-25	Akonni Biosystems, Inc.	Microarray system
WO2009136892A1 (en)	2008-05-09	2009-11-12	Akonni Biosystems	Microarray system
US8093018B2 (en)	2008-05-20	2012-01-10	Otsuka Pharmaceutical Co., Ltd.	Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
AR071874A1 (es)	2008-05-22	2010-07-21	Bristol Myers Squibb Co	Proteinas de dominio de armazon basadas en fibronectina multivalentes
US9109026B2 (en)	2008-06-03	2015-08-18	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
CN102112495A (zh) *	2008-06-03	2011-06-29	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
CA2729839A1 (en) *	2008-07-03	2010-01-07	Diane Retallack	High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
JP5674654B2 (ja) *	2008-07-08	2015-02-25	アッヴィ・インコーポレイテッド	プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
CN104402998A (zh)	2008-07-08	2015-03-11	昂考梅德药品有限公司	分离的抗体
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
CA2732782C (en)	2008-08-05	2019-02-26	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5
WO2010019702A2 (en)	2008-08-12	2010-02-18	Oncomed Pharmaceuticals, Inc.	Ddr1-binding agents and methods of use thereof
US8790642B2 (en)	2008-08-29	2014-07-29	Genentech, Inc.	Cross-reactive and bispecific anti-IL-17A/F antibodies
AR073538A1 (es)	2008-09-03	2010-11-17	Genentech Inc	Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
EP2334323A2 (de)	2008-09-10	2011-06-22	F. Hoffmann-La Roche AG	Zusammensetzungen und verfahren zur prävention des oxidativen abbaus von proteinen
TW201014605A (en)	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
HUE033438T2 (en) *	2008-09-26	2017-11-28	Ucb Biopharma Sprl	Biological products
GB0818228D0 (en)	2008-10-06	2008-11-12	Avecia Biolog Ltd	Purification process
SG10201605250SA (en)	2008-10-14	2016-08-30	Genentech Inc	Immunoglobulin variants and uses thereof
WO2010048192A2 (en)	2008-10-20	2010-04-29	Abbott Laboratories	Viral inactivation during purification of antibodies
NZ592095A (en) *	2008-10-20	2013-01-25	Abbott Lab	Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
CN102272599B (zh)	2008-11-11	2015-01-14	密执安大学评议会	抗cxcr1组合物和方法
WO2010056796A1 (en)	2008-11-12	2010-05-20	Theraclone Sciences, Inc.	Human m2e peptide immunogens
EP3693014A1 (de)	2008-11-13	2020-08-12	The General Hospital Corporation	Verfahren und zusammensetzungen zur regulierung der eisenhomöostase durch modulierung der bmp6-aktivität
KR20170015525A (ko)	2008-11-22	2017-02-08	제넨테크, 인크.	유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20110223169A1 (en) *	2008-11-26	2011-09-15	Stern Michael E	Il-17 antibody inhibitor for treating dry eye
US8211434B2 (en) *	2008-11-26	2012-07-03	Allergan, Inc.	KLK-13 antibody inhibitor for treating dry eye
KR20110097913A (ko) *	2008-12-04	2011-08-31	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
MX342591B (es)	2008-12-09	2016-10-05	Genentech Inc *	Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t.
AU2009335788A1 (en)	2008-12-17	2011-07-07	Genentech, Inc.	Hepatitis C virus combination therapy
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
WO2010075548A2 (en)	2008-12-23	2010-07-01	Genentech, Inc.	Immunoglobulin variants with altered binding to protein a
US20110142836A1 (en) *	2009-01-02	2011-06-16	Olav Mella	B-cell depleting agents for the treatment of chronic fatigue syndrome
BRPI1006141B8 (pt) *	2009-01-12	2021-05-25	Cytomx Therapeutics Llc	composições de anticorpo modificado, métodos para preparar e usar as mesmas
GB0902916D0 (en)	2009-02-20	2009-04-08	Fusion Antibodies Ltd	Antibody therapy
KR20110122859A (ko) *	2009-02-23	2011-11-11	그렌마크 파머수티칼스 에스. 아.	Ｃｄ１９에 결합하는 인간화된 항체 및 그것의 용도
BRPI1011384A2 (pt) *	2009-02-23	2016-03-15	Cytomx Therapeutics Inc	pro-proteinas e seus metodos de uso
GB0903168D0 (en)	2009-02-25	2009-04-08	Fusion Antibodies Ltd	Diagnostic method and kit
AR075798A1 (es)	2009-03-05	2011-04-27	Abbott Lab	Proteinas de union a il-17 (interleuquina 17)
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
MY152068A (en)	2009-03-20	2014-08-15	Genentech Inc	Bispecific anti-her antibodies
UA108199C2 (uk)	2009-03-25	2015-04-10		АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
DK3702371T5 (da)	2009-03-25	2024-08-26	Genentech Inc	Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
BRPI1006782A2 (pt)	2009-03-31	2016-03-15	3M Innovative Properties Co	composição, mistura polimerizável, artigo, método de uso do artigo e métodos para fabricar um suporte hidrofobicamente derivatizado
JP6132548B2 (ja)	2009-04-01	2017-05-24	ジェネンテック，インコーポレイテッド	抗ＦｃＲＨ５抗体および免疫接合体および使用方法
CA2752908A1 (en)	2009-04-01	2010-10-07	Genentech, Inc.	Treatment of insulin-resistant disorders
RU2598248C2 (ru)	2009-04-02	2016-09-20	Роше Гликарт Аг	Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
WO2010118243A2 (en)	2009-04-08	2010-10-14	Genentech, Inc.	Use of il-27 antagonists to treat lupus
WO2010115932A1 (en)	2009-04-08	2010-10-14	Novartis Ag	Combination for the treatment of bone loss
US9447467B2 (en)	2009-04-21	2016-09-20	Genetic Technologies Limited	Methods for obtaining fetal genetic material
CN102459340A (zh) *	2009-04-23	2012-05-16	特罗科隆科学有限公司	粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2010124113A1 (en)	2009-04-23	2010-10-28	Infinity Pharmaceuticals, Inc.	Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
JP2012525149A (ja)	2009-04-27	2012-10-22	オンコメッドファーマシューティカルズインコーポレイテッド	ヘテロ多量体分子を作製するための方法
US8680055B2 (en)	2009-06-03	2014-03-25	University Of Southern California	Methods for decreasing steroidogenesis in prostate cancer cells
US20120128698A1 (en)	2009-07-07	2012-05-24	Menno Van Lookeren Campagne	Diagnosis and treatment of autoimmune demyelinating diseases
CA2768711A1 (en)	2009-07-20	2011-01-27	Genentech, Inc.	Gene expression markers for crohn's disease
CA2768617C (en)	2009-07-24	2018-03-27	Akonni Biosystems	Flow cell device
AR077595A1 (es)	2009-07-27	2011-09-07	Genentech Inc	Tratamientos de combinacion
UY32808A (es) *	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
US20110027275A1 (en)	2009-07-31	2011-02-03	Napoleone Ferrara	Inhibition of tumor metastasis
NO2462158T3 (de)	2009-08-06	2018-06-09
WO2011018421A1 (en)	2009-08-10	2011-02-17	Morphosys Ag	Novel screening strategies for the identification of binders
US20110038871A1 (en)	2009-08-11	2011-02-17	Veena Viswanth	Ccr2 inhibitors for treating conditions of the eye
KR20180105258A (ko)	2009-08-11	2018-09-27	제넨테크, 인크.	글루타민-비함유 세포 배양 배지에서의 단백질의 생성
SG178419A1 (en)	2009-08-15	2012-04-27	Genentech Inc	Anti-angiogenesis therapy for the treatment of previously treated breast cancer
RU2570639C2 (ru)	2009-08-29	2015-12-10	Эббви Инк	Терапевтические dll4-связывающие белки
RU2012112550A (ru)	2009-09-01	2013-10-10	Эбботт Лэборетриз	Иммуноглобулины с двумя вариабельными доменами и их применение
ES2599076T3 (es)	2009-09-02	2017-01-31	Genentech, Inc.	Smoothened mutante y métodos de utilización del mismo
NZ598962A (en)	2009-09-16	2014-12-24	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
MX2012002909A (es)	2009-09-17	2012-04-19	Hoffmann La Roche	Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
US8470552B2 (en) *	2009-10-12	2013-06-25	Keck Graduate Institute	Strategy to reduce lactic acid production and control PH in animal cell culture
MX2012004415A (es)	2009-10-15	2012-05-08	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
ES2895226T3 (es)	2009-10-16	2022-02-18	Mereo Biopharma 5 Inc	Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
MX337666B (es)	2009-10-20	2016-03-14	Nestec Sa	Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
AU2010310585A1 (en)	2009-10-22	2012-05-03	Genentech, Inc.	Anti-hepsin antibodies and methods using same
MX2012004617A (es)	2009-10-22	2012-05-08	Genentech Inc	Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201124535A (en) *	2009-10-30	2011-07-16	Abbott Lab	SORF constructs and multiple gene expression
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20120316071A1 (en)	2009-11-04	2012-12-13	Vaughn Smider	Methods for affinity maturation-based antibody optimization
KR101968766B1 (ko) *	2009-11-05	2019-04-12	제넨테크, 인크.	이종 폴리펩티드의 분비를 위한 방법 및 조성물
AU2010324686B2 (en)	2009-11-30	2016-05-19	Genentech, Inc.	Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
RU2580038C2 (ru)	2009-12-04	2016-04-10	Дженентек, Инк.	Мультиспецифические антитела, аналоги антител, композиции и способы
JP5818805B2 (ja)	2009-12-11	2015-11-18	ジェネンテック，インコーポレイテッド	抗ｖｅｇｆ−ｃ抗体及びその使用方法
EP3616719A1 (de)	2009-12-21	2020-03-04	F. Hoffmann-La Roche AG	Antikörperformulierung
PL2516465T3 (pl)	2009-12-23	2016-11-30		Przeciwciała anty-bv8 i ich zastosowania
GB0922553D0 (en)	2009-12-23	2010-02-10	Fusion Antibodies Ltd	Prognostic marker
DK2519542T3 (en)	2009-12-28	2019-01-14	Onco Therapy Science Inc	ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
EP2523682B1 (de)	2010-01-13	2015-12-16	Oncomed Pharmaceuticals, Inc.	Notch1-bindende wirkstoffe und verfahren zu deren verwendung
ES2551871T3 (es)	2010-01-29	2015-11-24	Morphosys Ag	Genotecas combinatorias de anticuerpos de roedor
EP2534257B1 (de)	2010-02-12	2017-09-27	Oncomed Pharmaceuticals, Inc.	Verfahren zur identifikation und isolierung von zellen zur expression von polypeptiden
CA2787952C (en)	2010-02-23	2016-07-26	Genentech, Inc.	Anti-angiogenesis therapy for the treatment of ovarian cancer
PH12012501680A1 (en)	2010-02-23	2012-11-05	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
CA2790412C (en)	2010-02-24	2018-10-02	Immunogen, Inc.	Folate receptor 1 antibodies and immunoconjugates and uses thereof
JP5964249B2 (ja)	2010-03-02	2016-08-03	アッヴィ・インコーポレイテッド	治療用ｄｌｌ４結合タンパク質
MY177062A (en)	2010-03-12	2020-09-03	Debiopharm Int Sa	Cd37-binding molecules and immunoconjugates thereof
CN103124564B (zh)	2010-03-22	2016-11-09	弗·哈夫曼-拉罗切有限公司	对于稳定含有蛋白质的制剂有用的组合物和方法
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
RU2012148716A (ru)	2010-04-16	2014-05-27	Новартис Аг	Способы и композиции для улучшения оссеоинтеграции имплантата
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
ES2617777T5 (es)	2010-04-23	2022-10-13	Hoffmann La Roche	Producción de proteínas heteromultiméricas
JP2013525484A (ja)	2010-05-03	2013-06-20	ジェネンテック，インコーポレイテッド	タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
AU2011248354A1 (en)	2010-05-03	2012-11-08	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US9290573B2 (en)	2010-05-06	2016-03-22	Novartis Ag	Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
KR20130066632A (ko)	2010-05-06	2013-06-20	노파르티스 아게	치료적 저밀도 지단백질-관련 단백질 ６（ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
EP2975409B1 (de)	2010-05-10	2018-10-31	Academia Sinica	Zanamivir-phosphinat-kongenere mit antigrippewirkung und bestimmung der oseltamivir-empfänglichkeit von influenzaviren
KR101539683B1 (ko)	2010-05-14	2015-07-30	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
SG185737A1 (en)	2010-05-25	2013-01-30	Genentech Inc	Methods of purifying polypeptides
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
MX336109B (es)	2010-06-03	2016-01-08	Genentech Inc	Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
WO2011156369A2 (en) *	2010-06-07	2011-12-15	Dr. Reddy's Laboratories Ltd.	Purification of modified cytokines
US20110311527A1 (en)	2010-06-16	2011-12-22	Allergan, Inc.	IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CA2802756C (en)	2010-06-24	2021-05-04	Genentech, Inc.	Compositions and methods for stabilizing protein-containing formulations
US20120009196A1 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
SG187592A1 (en)	2010-07-23	2013-03-28	Univ Boston	Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
AR082461A1 (es)	2010-08-03	2012-12-12	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012019024A2 (en)	2010-08-04	2012-02-09	Immunogen, Inc.	Her3-binding molecules and immunoconjugates thereof
JP2013540701A (ja)	2010-08-12	2013-11-07	セラクローンサイエンシーズ，インコーポレイテッド	抗赤血球凝集素抗体組成物およびその使用方法
EP2420250A1 (de)	2010-08-13	2012-02-22	Universitätsklinikum Münster	Anti-Syndecan-4-Antikörper
MX2013001267A (es)	2010-08-13	2013-04-10	Genentech Inc	ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
CA2808154A1 (en)	2010-08-13	2012-02-16	Medimmmune Limited	Monomeric polypeptides comprising variant fc regions and methods of use
WO2012022734A2 (en)	2010-08-16	2012-02-23	Medimmune Limited	Anti-icam-1 antibodies and methods of use
EP2606334B1 (de)	2010-08-20	2018-04-25	GE Healthcare Limited	Qualitätskontrollkassette und -verfahren für radioaktive arzneimittel
BR112013004012B1 (pt)	2010-08-20	2021-03-23	Novartis Ag	Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
JP5758004B2 (ja)	2010-08-24	2015-08-05	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
WO2012027570A2 (en)	2010-08-26	2012-03-01	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
WO2012030904A2 (en)	2010-08-31	2012-03-08	Theraclone Sciences, Inc.	Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012030512A1 (en) *	2010-09-03	2012-03-08	Percivia Llc.	Flow-through protein purification process
WO2012032043A1 (en)	2010-09-07	2012-03-15	Areva Med Llc	212 pb imaging
WO2012033953A1 (en)	2010-09-08	2012-03-15	Halozyme, Inc.	Methods for assessing and identifying or evolving conditionally active therapeutic proteins
US8551479B2 (en)	2010-09-10	2013-10-08	Oncomed Pharmaceuticals, Inc.	Methods for treating melanoma
WO2012039756A2 (en) *	2010-09-24	2012-03-29	Full Spectrum Genetics, Inc.	Method of analyzing binding interactions
DK2625197T3 (en)	2010-10-05	2016-10-03	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
EP3214442A1 (de)	2010-10-25	2017-09-06	F. Hoffmann-La Roche AG	Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
WO2012071436A1 (en)	2010-11-24	2012-05-31	Genentech, Inc.	Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012069466A1 (en)	2010-11-24	2012-05-31	Novartis Ag	Multispecific molecules
WO2012075333A2 (en)	2010-12-02	2012-06-07	Prometheus Laboratories Inc.	Her2delta16 peptides
EP2655417A2 (de)	2010-12-21	2013-10-30	AbbVie Inc.	Il-1 alpha- und -beta-bispezifische immunglobuline mit zweifacher variabler domäne und ihre verwendung
EP2656077A1 (de)	2010-12-23	2013-10-30	Nestec S.A.	Wirkstoffauswahl für eine bösartige krebstherapie anhand von antikörper-arrays
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2655402A1 (de)	2010-12-23	2013-10-30	Intercell Austria AG	Oprf/i-mittel und ihre verwendung bei stationären und anderen patienten
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
RU2013131825A (ru)	2011-01-10	2015-02-20	Зе Реджентс Оф Зе Юниверсити Оф Мичиган	Ингибитор фактора стволовых клеток
AR085138A1 (es)	2011-02-04	2013-09-11	Genentech Inc	VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
WO2012112489A2 (en)	2011-02-14	2012-08-23	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
WO2012119989A2 (en)	2011-03-04	2012-09-13	Oryzon Genomics, S.A.	Methods and antibodies for the diagnosis and treatment of cancer
WO2012120004A1 (en)	2011-03-07	2012-09-13	F. Hoffmann-La Roche Ag	In vivo selection of therapeutically active antibodies
WO2012119999A1 (en)	2011-03-07	2012-09-13	F. Hoffmann-La Roche Ag	Means and methods for in vivo testing of therapeutic antibodies
US9920110B2 (en)	2011-03-09	2018-03-20	Cell Signaling Technology, Inc.	Methods and reagents for creating monoclonal antibodies
CN103533929A (zh)	2011-03-15	2014-01-22	特罗科隆科学有限公司	用于流行性感冒的治疗和诊断的组合物和方法
EP2697369B1 (de)	2011-03-25	2018-06-27	F.Hoffmann-La Roche Ag	Neue proteinreinigungsverfahren
EP3412309A1 (de)	2011-03-31	2018-12-12	F. Hoffmann-La Roche AG	Verfahren zur verabreichung von beta7-integrin-antagonisten
AP2013007180A0 (en)	2011-04-25	2013-10-31	Advanced Bioscience Lab Inc	Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
EP2702077A2 (de)	2011-04-27	2014-03-05	AbbVie Inc.	Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
JP2014515759A (ja)	2011-04-29	2014-07-03	ノバルティスアーゲー	扁平上皮がんを治療する方法関連出願
AU2012250924B2 (en)	2011-05-02	2017-05-25	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2012155134A2 (en)	2011-05-12	2012-11-15	The Johns Hopkins University	Assay reagents for a neurogranin diagnostic kit
IL276182B (en)	2011-05-17	2022-09-01	Univ Rockefeller	Human immunodeficiency virus neutralizing antibodies and methods of use thereof
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
EP2540828A1 (de)	2011-06-30	2013-01-02	Gene Signal International SA	Zusammensetzung mit Inhibitoren von IRS-1 und VEGF
CN108159426A (zh)	2011-06-30	2018-06-15	基因信号国际公司	含有irs-1抑制剂和vegf抑制剂的组合物
JP2013040160A (ja)	2011-07-01	2013-02-28	Genentech Inc	自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
CA3158257A1 (en)	2011-07-11	2013-01-17	Ichnos Sciences SA	Antibodies that bind to ox40 and their uses
US9120858B2 (en)	2011-07-22	2015-09-01	The Research Foundation Of State University Of New York	Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en)	2011-07-22	2013-01-31	The Research Foundation Of State University Of New York	Antibodies to the b12-transcobalamin receptor
US20130022551A1 (en)	2011-07-22	2013-01-24	Trustees Of Boston University	DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9493549B2 (en)	2011-07-25	2016-11-15	The Rockefeller University	Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
US9890207B2 (en)	2011-07-25	2018-02-13	California Institute Of Technology	Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
BR122022000334B1 (pt)	2011-08-01	2023-03-21	Genentech, Inc	Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
JP2014525412A (ja)	2011-08-17	2014-09-29	ジェネンテック，インコーポレイテッド	難治性腫瘍における血管新生の阻害
US8822651B2 (en)	2011-08-30	2014-09-02	Theraclone Sciences, Inc.	Human rhinovirus (HRV) antibodies
ES2553456T3 (es)	2011-09-02	2015-12-09	Nestec S.A.	Perfilado de proteínas de ruta de señal para determinar una eficacia terapéutica
CN107722122B (zh)	2011-09-23	2022-05-27	昂考梅德药品有限公司	Vegf/dll4结合剂及其应用
US9575073B2 (en)	2011-10-10	2017-02-21	Rutgers, The State University Of New Jersey	Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2766397B1 (de)	2011-10-11	2018-05-30	F.Hoffmann-La Roche Ag	Verbesserter zusammenbau bispezifischer antikörper
EP2766037A4 (de)	2011-10-12	2015-08-05	Scripps Research Inst	Hiv-1 gp-120-mini-v3-schleife und verwendungen davon
EP2581388A1 (de)	2011-10-14	2013-04-17	Centre National de la Recherche Scientifique (CNRS)	Antikörper gegen sPLA2-V und Gebrauch davon
ES2769786T3 (es)	2011-10-14	2020-06-29	Recordati Ag	Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
EP2771360A1 (de)	2011-10-24	2014-09-03	AbbVie Inc.	Gegen sclerostin gerchtet immunbinder
AR088514A1 (es)	2011-10-24	2014-06-18	Abbvie Inc	Inmunoligantes biespecificos dirigidos contra tnf
AU2012323995B2 (en)	2011-11-02	2016-06-09	Genentech, Inc.	Overload and elute chromatography
BR112014012539B1 (pt)	2011-11-23	2022-12-20	Medimmune, Llc	Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
JP6138813B2 (ja)	2011-11-28	2017-05-31	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	抗ｐｄ−ｌ１抗体及びその使用
WO2013082511A1 (en)	2011-12-02	2013-06-06	Genentech, Inc.	Methods for overcoming tumor resistance to vegf antagonists
JP2015500829A (ja)	2011-12-05	2015-01-08	ノバルティスアーゲー	上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
EP2788380B1 (de)	2011-12-05	2019-08-28	Novartis AG	Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
EP2602265A1 (de)	2011-12-07	2013-06-12	Centre National de la Recherche Scientifique (CNRS)	Antikörper gegen Anti-sPLA2-X und Verwendungen damit
CN104284680A (zh)	2011-12-15	2015-01-14	芝加哥大学	使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
AU2012356170B2 (en)	2011-12-21	2016-06-16	Novartis Ag	Compositions and methods for antibodies targeting Factor P
CN104125963B (zh)	2011-12-22	2018-08-17	弗·哈夫曼-拉罗切有限公司	使用离子交换膜层析改进下游蛋白质纯化步骤的方法
WO2013091903A1 (en)	2011-12-22	2013-06-27	Novo Nordisk A/S	Anti-crac channel antibodies
US9120870B2 (en)	2011-12-30	2015-09-01	Abbvie Inc.	Dual specific binding proteins directed against IL-13 and IL-17
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
WO2013106489A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Humanized antibodies with ultralong cdr3s
US20140050720A1 (en)	2012-01-09	2014-02-20	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
TW201334789A (zh)	2012-01-31	2013-09-01	Genentech Inc	抗ｉｇｅ抗體及其使用方法
EP2812357B1 (de)	2012-02-10	2020-11-04	F.Hoffmann-La Roche Ag	Einzelketten-antikörper und andere heteromultimere
CN104379602B (zh)	2012-03-08	2017-05-03	哈洛齐梅公司	具有条件活性的抗表皮生长因子受体抗体及其使用方法
EP2641916A1 (de)	2012-03-23	2013-09-25	Centre National de la Recherche Scientifique (C.N.R.S)	Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
EP2830659A1 (de)	2012-03-27	2015-02-04	Novartis AG	Behandlung von fibrose
CN104220457A (zh)	2012-03-27	2014-12-17	霍夫曼-拉罗奇有限公司	涉及her3抑制剂的诊断和治疗
EP2833900B1 (de)	2012-04-01	2018-09-19	Technion Research & Development Foundation Limited	Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
AU2013267267B2 (en)	2012-05-31	2017-10-26	Genentech, Inc.	Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
MX2014014894A (es)	2012-06-04	2015-02-20	Irm Llc	Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
AP2014008145A0 (en)	2012-06-08	2014-12-31	Glenmark Pharmaceuticals Sa	Humanized anti-trkA antibodies with animo acid substitutions
WO2013192589A1 (en)	2012-06-21	2013-12-27	California Institute Of Technology	Antibodies targeting hiv escape mutants
JOP20130186B1 (ar)	2012-06-22	2021-08-17	Takeda Vaccines Montana Inc	تنقية الجزيئات الشبيهة بالفيروسات
CA2871880A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
KR20150030744A (ko)	2012-06-27	2015-03-20	에프. 호프만-라 로슈 아게	표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
WO2014011955A2 (en)	2012-07-12	2014-01-16	Abbvie, Inc.	Il-1 binding proteins
WO2014018375A1 (en)	2012-07-23	2014-01-30	Xenon Pharmaceuticals Inc.	Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CA2916638C (en)	2012-07-31	2021-01-12	The Brigham And Women's Hospital, Inc.	Modulation of the immune response
US9297806B2 (en)	2012-08-01	2016-03-29	The Johns Hopkins University	5-hydroxymethylcytosine in human cancer
FR2994390B1 (fr)	2012-08-10	2014-08-15	Adocia	Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
JP6302909B2 (ja)	2012-08-18	2018-03-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	シアリダーゼの同定および画像化のための細胞透過性プローブ
PL3333195T3 (pl)	2012-08-21	2021-02-22	Janssen Pharmaceutica Nv	Przeciwciała względem kwetiapiny i ich zastosowania
CN109400708A (zh)	2012-08-21	2019-03-01	詹森药业有限公司	奥氮平半抗原的抗体及其用途
ES2807902T3 (es)	2012-08-21	2021-02-24	Janssen Pharmaceutica Nv	Anticuerpos para olanzapina y uso de los mismos
PL3321254T3 (pl)	2012-08-21	2021-01-11	Janssen Pharmaceutica Nv	Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
EP2888277A4 (de)	2012-08-21	2016-05-18	Ortho Clinical Diagnostics Inc	Antikörper gegen paliperidon und verwendung davon
AU2013305827A1 (en)	2012-08-21	2015-03-05	Academia Sinica	Benzocyclooctyne compounds and uses thereof
WO2014031635A1 (en)	2012-08-21	2014-02-27	Ortho-Clinical Diagnostics, Inc	Antibodies to aripiprazole haptens and use thereof
ES2666000T3 (es)	2012-08-21	2018-04-30	Janssen Pharmaceutica, N.V.	Anticuerpos para aripiprazol y uso de los mismos
CA2882597C (en)	2012-08-21	2020-04-14	Ortho-Clinical Diagnostics, Inc.	Antibodies to quetiapine haptens and use thereof
US20140057297A1 (en)	2012-08-21	2014-02-27	Janssen Pharmaceutica Nv	Antibodies to Paliperidone Haptens and Use Thereof
ES2691092T3 (es)	2012-08-21	2018-11-23	Janssen Pharmaceutica Nv	Anticuerpos contra la risperidona y uso de los mismos
PL2888284T3 (pl)	2012-08-21	2023-02-27	Janssen Pharmaceutica Nv	Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
RS60217B1 (sr)	2012-08-31	2020-06-30	Immunogen Inc	Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
BR112015004467A2 (pt)	2012-09-02	2017-03-21	Abbvie Inc	método para controlar a heterogeneidade de proteínas
ES2807173T3 (es)	2012-09-10	2021-02-22	Int Aids Vaccine Initiative	Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos
CN118955699A (zh)	2012-10-18	2024-11-15	洛克菲勒大学	广泛中和性抗hiv抗体
AU2013337811A1 (en)	2012-10-31	2015-05-14	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a DLL4 antagonist
US9163093B2 (en)	2012-11-01	2015-10-20	Abbvie Inc.	Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
WO2014078729A1 (en)	2012-11-15	2014-05-22	Genentech, Inc.	IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
CN109517063B (zh)	2012-12-05	2022-07-01	诺华股份有限公司	靶向epo的抗体的组合物和方法
KR20150095684A (ko)	2012-12-18	2015-08-21	노파르티스 아게	히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
US9458244B2 (en)	2012-12-28	2016-10-04	Abbvie Inc.	Single chain multivalent binding protein compositions and methods
CA2896548A1 (en)	2012-12-28	2014-07-03	Abbvie, Inc.	Multivalent binding protein compositions
PE20151289A1 (es)	2013-01-02	2015-10-05	Glenmark Pharmaceuticals Sa	Anticuerpos que se unen al tl1a y sus usos
EP2948177A1 (de)	2013-01-22	2015-12-02	AbbVie Inc.	Verfahren zur optimierung der domänenstabilität von bindungsproteinen
WO2014116846A2 (en)	2013-01-23	2014-07-31	Abbvie, Inc.	Methods and compositions for modulating an immune response
WO2014118705A1 (en)	2013-01-31	2014-08-07	Novartis Ag	Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014120975A1 (en)	2013-02-01	2014-08-07	California Institute Of Technology	Antibody-mediated immunocontraception
WO2014124258A2 (en)	2013-02-08	2014-08-14	Irm Llc	Specific sites for modifying antibodies to make immunoconjugates
JP6609477B2 (ja)	2013-02-08	2019-11-20	ノバルティスアーゲー	イムノコンジュゲートを調製する修飾抗体のための特定部位
KR102182488B1 (ko)	2013-02-25	2020-11-24	제넨테크, 인크.	약물 내성 akt 돌연변이체의 검출 및 치료를 위한 방법 및 조성물
WO2014143205A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9809645B2 (en)	2013-03-12	2017-11-07	Zenyaku Kogyo Kabushikikaisha	Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
WO2014141064A1 (en)	2013-03-13	2014-09-18	Novartis Ag	Notch2 binding molecules for treating respiratory diseases
US10023608B1 (en)	2013-03-13	2018-07-17	Amgen Inc.	Protein purification methods to remove impurities
US9498532B2 (en)	2013-03-13	2016-11-22	Novartis Ag	Antibody drug conjugates
AU2014243783B2 (en)	2013-03-13	2018-12-13	Genentech, Inc.	Antibody formulations
SG11201507043SA (en)	2013-03-13	2015-10-29	Genentech Inc	Formulations with reduced oxidation
AR095399A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida, método
RU2019137020A (ru)	2013-03-13	2021-01-14	Дженентек, Инк.	Составы со сниженным окислением
US20140314778A1 (en)	2013-03-13	2014-10-23	Genentech, Inc.	Formulations with reduced oxidation
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9790478B2 (en)	2013-03-14	2017-10-17	Abbott Laboratories	HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
WO2014159239A2 (en)	2013-03-14	2014-10-02	Novartis Ag	Antibodies against notch 3
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
JP6739329B2 (ja)	2013-03-14	2020-08-12	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	Ｈｃｖコア脂質結合ドメインモノクローナル抗体
CN105228649B (zh)	2013-03-14	2019-01-18	雅培制药有限公司	Hcv抗原-抗体组合测定和方法以及用在其中的组合物
KR20150131173A (ko)	2013-03-15	2015-11-24	노파르티스 아게	항체 약물 접합체
CN105121628B (zh)	2013-03-15	2020-03-24	豪夫迈·罗氏有限公司	具有抗氧化剂的细胞培养组合物和多肽生产方法
EP3936515A1 (de) *	2013-03-15	2022-01-12	Biogen MA Inc.	Hydrophobe interaktionsproteinchromatografie unter salzfreien bedingungen
US9062108B2 (en)	2013-03-15	2015-06-23	Abbvie Inc.	Dual specific binding proteins directed against IL-1 and/or IL-17
WO2014145091A1 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Cell culture media and methods of antibody production
US20140283157A1 (en)	2013-03-15	2014-09-18	Diadexus, Inc.	Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
EP3495814A3 (de)	2013-03-27	2019-07-17	F. Hoffmann-La Roche AG	Verwendung von biomarkern zur beurteilung der behandlung von magen-darm-entzündungserkrankungen mit beta7-integrin-antagonisten
WO2014169076A1 (en)	2013-04-09	2014-10-16	Annexon,,Inc.	Methods of treatment for neuromyelitis optica
MX368142B (es)	2013-04-30	2019-09-20	Intas Pharmaceuticals Ltd	Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
AU2014269961A1 (en)	2013-05-24	2015-11-26	Société des Produits Nestlé S.A.	Pathway specific markers for diagnosing irritable bowel syndrome
AU2014278537B2 (en)	2013-06-12	2018-04-19	The General Hospital Corporation	Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096713A1 (es)	2013-06-25	2016-01-27	Cadila Healthcare Ltd	Proceso de purificación para anticuerpos monoclonales
US10086054B2 (en)	2013-06-26	2018-10-02	Academia Sinica	RM2 antigens and use thereof
EP3013347B1 (de)	2013-06-27	2019-12-11	Academia Sinica	Glykankonjugate und verwendung davon
SG10201710758PA (en)	2013-07-09	2018-02-27	Annexon Inc	Anti-complement factor c1q antibodies and uses thereof
WO2015006554A1 (en)	2013-07-10	2015-01-15	The Regents Of The University Of Michigan	Therapeutic antibodies and uses thereof
MX368107B (es)	2013-07-12	2019-09-18	Genentech Inc	Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
EP3789036A1 (de)	2013-07-16	2021-03-10	F. Hoffmann-La Roche AG	Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und tigit-inhibitoren
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CN105814074B (zh)	2013-07-18	2020-04-21	图鲁斯生物科学有限责任公司	具有超长互补决定区的人源化抗体
CR20160132A (es)	2013-08-12	2016-08-25	Genentech Inc	Composiciones y método para tratar condiciones asociadas con el complemento
RS62240B1 (sr)	2013-08-30	2021-09-30	Immunogen Inc	Antitela i testovi za detekciju folatnog receptora 1
MX2016002798A (es)	2013-09-05	2016-07-21	Genentech Inc	Metodo para reutilizacion de cromatografia.
JP6486368B2 (ja)	2013-09-06	2019-03-20	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
IL312865B1 (en)	2013-09-11	2025-02-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-reducing agents
JP6282745B2 (ja)	2013-09-12	2018-02-21	ハロザイムインコーポレイテッド	修飾抗上皮成長因子受容体抗体およびその使用法
AU2014318615B2 (en)	2013-09-13	2020-03-12	Genentech, Inc.	Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl)	2013-09-13	2022-06-27	F.Hoffmann-La Roche Ag	Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
RU2666141C2 (ru)	2013-09-17	2018-09-06	Оби Фарма, Инк.	Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
LT3049441T (lt)	2013-09-27	2020-02-10	F. Hoffmann-La Roche Ag	Anti-pdl1 antikūnų kompozicija
US9243294B2 (en)	2013-09-30	2016-01-26	Hadasit Medical Research Services And Development Ltd.	Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
WO2015050959A1 (en)	2013-10-01	2015-04-09	Yale University	Anti-kit antibodies and methods of use thereof
CN118005782A (zh)	2013-10-02	2024-05-10	免疫医疗有限责任公司	中和抗甲型流感抗体及其用途
EP3052640A2 (de)	2013-10-04	2016-08-10	AbbVie Inc.	Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
MX2016006726A (es)	2013-11-25	2016-12-16	Ccam Biotherapeutics Ltd	Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
EP3074039A4 (de)	2013-11-26	2017-10-11	The Brigham and Women's Hospital, Inc.	Zusammensetzungen und verfahren zur modulierung einer immunreaktion
LT3079719T (lt)	2013-12-09	2019-12-10	Allakos Inc	Antikūnai prieš siglec-8 ir jų panaudojimo būdai
JP2017505756A (ja)	2013-12-13	2017-02-23	ザジェネラルホスピタルコーポレイション	可溶性高分子量（ｈｍｗ）タウ種およびその用途
EP3083687A2 (de)	2013-12-17	2016-10-26	F. Hoffmann-La Roche AG	Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
CA2931812A1 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Methods of treating cancers using pd-1 axis binding antagonists and taxanes
JP6636925B2 (ja)	2013-12-17	2020-01-29	ノバルティスアーゲー	細胞障害性ペプチドおよびその抱合体
KR20160089532A (ko)	2013-12-17	2016-07-27	제넨테크, 인크.	Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
RU2020129339A (ru)	2013-12-20	2020-10-02	Дженентек, Инк.	Антитела с двойной специфичностью
WO2015103026A2 (en)	2014-01-03	2015-07-09	The Regents Of The University Of Michigan	Treatment of neurological disorders
EP2891657A1 (de)	2014-01-07	2015-07-08	Centre National de la Recherche Scientifique (CNRS)	Durch ionische Flüssigkeiten unterstützte Organozinnreagenzien zur Herstellung von radioaktiven Arzneimittelverbindungen
WO2016114819A1 (en)	2015-01-16	2016-07-21	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
CN106459920B (zh)	2014-01-16	2020-10-30	中央研究院	治疗及检测癌症的组合物及方法
EP2896400A1 (de)	2014-01-17	2015-07-22	Université Catholique De Louvain	Verfahren zur Erhöhung der Bioverfügbarkeit von inhaliertem Verbindungen
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
EP3102197B1 (de)	2014-02-04	2018-08-29	Genentech, Inc.	Smoothened-mutant und verfahren zur verwendung davon
WO2015120130A1 (en)	2014-02-07	2015-08-13	Novartis Ag	Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
CA2938767A1 (en)	2014-02-19	2015-08-27	University Of Tennessee Research Foundation	Antibody for skewing sex ratio and methods of use thereof
JP6825909B2 (ja)	2014-02-28	2021-02-03	アラコスインコーポレイテッド	シグレック−８関連疾患を処置するための方法および組成物
MX2016011627A (es)	2014-03-12	2016-11-29	Novartis Ag	Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
ES2897765T3 (es)	2014-03-14	2022-03-02	Hoffmann La Roche	Procedimientos y composiciones para la secreción de polipéptidos heterólogos
US20170107300A1 (en)	2014-03-21	2017-04-20	The Brigham And Women's Hospital, Inc.	Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
AU2015235986B2 (en)	2014-03-27	2020-12-03	Genentech, Inc.	Methods for diagnosing and treating inflammatory bowel disease
JP6562942B2 (ja)	2014-03-27	2019-08-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	反応性標識化合物およびその使用
WO2015145449A2 (en)	2014-03-27	2015-10-01	Yeda Research And Development Co. Ltd.	T-cell receptor cdr3 peptides and antibodies
MX2016012779A (es)	2014-03-31	2017-04-27	Genentech Inc	Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
CN111560071B (zh)	2014-04-08	2023-09-05	波士顿制药有限公司	对il-21具有特异性的结合分子及其用途
MX2016012830A (es)	2014-04-11	2017-01-05	Medimmune Llc	Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
EP3148567A4 (de)	2014-04-25	2018-01-10	The Brigham and Women's Hospital, Inc.	Verfahren zur manipulation von alpha-fetoprotein (afp)
US20170045528A1 (en)	2014-04-25	2017-02-16	The Brigham And Women's Hospital, Inc.	Compositions and methods for treating subjects with immune-mediated diseases
US11427647B2 (en)	2014-04-27	2022-08-30	Famewave Ltd.	Polynucleotides encoding humanized antibodies against CEACAM1
KR102452349B1 (ko)	2014-04-27	2022-10-11	페임웨이브 리미티드	Ceacam1에 대한 인간화 항체
CN106471117A (zh)	2014-05-06	2017-03-01	豪夫迈·罗氏有限公司	使用哺乳动物细胞产生异多聚体蛋白
AU2015259465A1 (en)	2014-05-13	2016-11-17	Bioatla Llc	Conditionally active biological proteins
JP6894239B2 (ja)	2014-05-27	2021-06-30	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
CA2950415A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950440A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-her2 glycoantibodies and uses thereof
EP3154582A4 (de)	2014-05-28	2018-01-10	Academia Sinica	Anti-tnf-alpha-glycoantikörper und verwendungen davon
EP3148581B1 (de)	2014-05-30	2019-10-09	Henlius Biotech Co., Ltd.	Anti-egfr-antikörper
WO2015191760A2 (en)	2014-06-10	2015-12-17	Abbvie, Inc.	Compositions and methods for treating rheumatoid arthritis
MX2016016515A (es)	2014-06-13	2017-04-27	Novartis Ag	Derivados de auristatina y conjugados de los mismos.
EP2957571B1 (de)	2014-06-17	2018-08-15	Centre National De La Recherche Scientifique (Cnrs)	Monoklonale anti-pvhl-antikörper und anwendungen davon
EP3160991A2 (de)	2014-06-25	2017-05-03	Novartis AG	Zusammensetzungen und verfahren für proteine mit langer wirkung
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
EP3164194B1 (de)	2014-07-03	2021-11-24	Yale University	Dickkopf2 (dkk2)-hemmung zur unterdrückung der tumorbildung
AR101210A1 (es)	2014-07-15	2016-11-30	Genentech Inc	Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
US20170291956A1 (en)	2014-07-16	2017-10-12	David Livingston	HER3 Inhibition in Low-grade Serous Ovarian Cancers
SG11201700365TA (en)	2014-07-24	2017-02-27	Genentech Inc	Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
US10786578B2 (en)	2014-08-05	2020-09-29	Novartis Ag	CKIT antibody drug conjugates
JO3565B1 (ar)	2014-08-07	2020-07-05	Novartis Ag	الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EP3194437B1 (de)	2014-08-07	2021-01-20	Novartis AG	Antikörper gegen angiopoietinähnliches protein 4 und deren verwendung
US20170240631A1 (en)	2014-08-08	2017-08-24	Alector Llc	Anti-trem2 antibodies and methods of use thereof
AU2015302959B2 (en)	2014-08-12	2018-09-20	Novartis Ag	Anti-CDH6 antibody drug conjugates
EP4074735A1 (de)	2014-08-28	2022-10-19	BioAtla, Inc.	Bedingt aktive chimäre antigenrezeptoren für modifizierte t-zellen
EP3186281B1 (de)	2014-08-28	2019-04-10	Halozyme, Inc.	Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
US11111288B2 (en)	2014-08-28	2021-09-07	Bioatla, Inc.	Conditionally active chimeric antigen receptors for modified t-cells
BR112017004131A2 (pt)	2014-09-03	2017-12-12	Bioatla Llc	método de produção de uma proteína biológica condicionalmente ativa, proteína biológica condicionalmente ativa, receptor de antígeno quimérico, e, célula citotóxica.
AU2015315294B2 (en)	2014-09-08	2020-09-17	Academia Sinica	Human iNKT cell activation using glycolipids
WO2016038550A1 (en)	2014-09-11	2016-03-17	Novartis Ag	Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP7072384B2 (ja)	2014-09-15	2022-05-20	ジェネンテック，インコーポレイテッド	抗体製剤
WO2016044697A1 (en)	2014-09-19	2016-03-24	The Johns Hopkins University	Biomarkers of cognitive dysfunction
TWI700300B (zh)	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
SG11201702614SA (en)	2014-10-01	2017-04-27	Eagle Biolog Inc	Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
TW201628649A (zh)	2014-10-09	2016-08-16	再生元醫藥公司	減少醫藥調配物中微可見顆粒之方法
KR102122463B1 (ko)	2014-10-14	2020-06-15	할로자임, 아이엔씨	아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
DK3212233T3 (da)	2014-10-31	2020-07-27	Oncomed Pharm Inc	Kombinationsterapi til behandling af sygdom
MX2017005930A (es)	2014-11-05	2017-06-30	Genentech Inc	Metodo de produccion de proteinas de cadena doble en bacterias.
EP3215533A2 (de)	2014-11-05	2017-09-13	F. Hoffmann-La Roche AG	Anti-fgfr2/3-antikörper und verfahren zur verwendung davon
NZ769628A (en)	2014-11-05	2024-10-25	Annexon Inc	Humanized anti-complement factor c1q antibodies and uses thereof
CN107075548B (zh)	2014-11-05	2021-08-10	基因泰克公司	在细菌中产生双链蛋白质的方法
MX2017005929A (es)	2014-11-06	2017-11-20	Genentech Inc	Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
WO2016071856A1 (en)	2014-11-06	2016-05-12	Novartis Ag	Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
JP2018500882A (ja)	2014-11-10	2018-01-18	ジェネンテック，インコーポレイテッド	腎症の動物モデルおよびそれを治療するための薬剤
SMT202100353T1 (it)	2014-11-10	2021-07-12	Medimmune Ltd	Molecole di legame specifiche per cd73 e relativi usi
CN107172879B (zh)	2014-11-10	2021-11-05	豪夫迈·罗氏有限公司	抗白细胞介素-33抗体及其用途
US20160129108A1 (en)	2014-11-11	2016-05-12	Medimmune Limited	Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
US9526768B2 (en)	2014-11-13	2016-12-27	Jennifer Mai	Compositions for the treatment of cancer
CN106999583A (zh)	2014-11-17	2017-08-01	豪夫迈·罗氏有限公司	包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
WO2016079708A1 (en)	2014-11-19	2016-05-26	Nestec S.A.	Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
EP3221445B1 (de)	2014-11-20	2021-07-14	The Regents of The University of California	Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
EP3227446A1 (de)	2014-12-01	2017-10-11	Novartis AG	Zusammensetzungen und verfahren zur diagnose und behandlung von prostatakrebs
US20170269092A1 (en)	2014-12-02	2017-09-21	Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh	Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CN107001482B (zh)	2014-12-03	2021-06-15	豪夫迈·罗氏有限公司	多特异性抗体
EP3029032A1 (de)	2014-12-05	2016-06-08	Centre National de la Recherche Scientifique (CNRS)	Bifunktionelle Do2pa-Derivate, Chelate mit metallischen Kationen und Verwendung davon
EP3227337A1 (de)	2014-12-05	2017-10-11	F. Hoffmann-La Roche AG	Verfahren und zusammensetzungen zur krebsbehandlung mit pd-1-achsenantagonisten und hpk1-antagonisten
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
US10703813B2 (en)	2014-12-19	2020-07-07	Universite De Nantes	Anti IL-34 antibodies
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
CN107206074B (zh)	2014-12-22	2023-12-01	西雅图免疫公司	双特异性四价抗体及其制备和使用方法
GB2557389B (en)	2015-01-14	2020-12-23	Brigham & Womens Hospital Inc	Treatment of cancer with anti-lap monoclonal antibodies
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US10342858B2 (en)	2015-01-24	2019-07-09	Academia Sinica	Glycan conjugates and methods of use thereof
CN112430268A (zh)	2015-01-24	2021-03-02	中央研究院	癌症标记及其使用方法
EP3250927B1 (de)	2015-01-28	2020-02-19	H. Hoffnabb-La Roche Ag	Genexpressionsmarker und behandlung von multipler sklerose
JP6942633B2 (ja)	2015-01-30	2021-09-29	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
MA41451A (fr)	2015-02-04	2017-12-12	Univ Washington	Constructions anti-tau
JP2018512597A (ja)	2015-02-04	2018-05-17	ジェネンテック，インコーポレイテッド	突然変異体スムースンド及びその使用方法
AU2016219534B2 (en)	2015-02-09	2021-07-01	Massachusetts Institute Of Technology	Multi-specific antibodies with affinity for human A33 antigen and dota metal complex and uses thereof
US20170151281A1 (en)	2015-02-19	2017-06-01	Batu Biologics, Inc.	Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
TWI691512B (zh) *	2015-02-20	2020-04-21	日商橘生藥品工業股份有限公司	Ｆｃ融合高親和性ＩｇＥ受體α鏈
AU2016223584B2 (en)	2015-02-23	2020-11-19	Enrico GIRAUDO	Non-natural Semaphorins 3 and their medical use
CN107257693A (zh)	2015-02-26	2017-10-17	豪夫迈·罗氏有限公司	治疗Crohn病的整联蛋白β7拮抗剂和方法
IL278423B2 (en)	2015-02-26	2024-04-01	Merck Patent Gmbh	Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
AU2016230018A1 (en)	2015-03-06	2017-09-21	Genentech, Inc.	Ultrapurified DsbA and DsbC and methods of making and using the same
EP3277306B1 (de)	2015-04-01	2023-02-22	Hadasit Medical Research Services and Development Ltd.	Inhibitoren der neuroligin-4-neurexin-1-beta-protein-protein-wechselwirkung zur verwendung in der behandlung von lebererkrankungen
US11279768B1 (en)	2015-04-03	2022-03-22	Precision Biologics, Inc.	Anti-cancer antibodies, combination therapies, and uses thereof
CA2982115A1 (en)	2015-04-06	2016-10-13	President And Fellows Of Harvard College	Compositions and methods for non-myeloablative conditioning
PT3280441T (pt)	2015-04-07	2021-11-30	Alector Llc	Anticorpos anti-sortilina e métodos para a sua utilização
JP6955445B2 (ja)	2015-04-07	2021-10-27	ジェネンテック，インコーポレイテッド	アゴニスト性の活性を有する抗原結合複合体及びその使用方法
US11215616B2 (en)	2015-04-10	2022-01-04	National Institutes Of Health (Nih), (Dhhs), U.S. Government	Methods of determining patient populations amenable to immunomodulatory treatment of cancer
WO2016172485A2 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
CN115932273A (zh)	2015-04-24	2023-04-07	豪夫迈·罗氏有限公司	鉴定包含结合多肽的细菌的方法
JP6963508B2 (ja)	2015-05-11	2021-11-10	ジェネンテック，インコーポレイテッド	ループス腎炎を治療する組成物及び方法
EP3718569B1 (de)	2015-05-22	2023-05-03	Translational Drug Development, LLC	Benzamid- und aktivverbindungszusammensetzungen und verwendungsmethoden
US10966414B2 (en)	2015-05-26	2021-04-06	California Institute Of Technology	Population control using engineered translocations
EP3795679A1 (de)	2015-05-28	2021-03-24	Genentech, Inc.	Zellbasierter test zum nachweis von anti-cd3-homodimeren
EP3763827A1 (de)	2015-05-29	2021-01-13	F. Hoffmann-La Roche AG	Pd-l1-promotormethylierung bei krebs
WO2016196679A1 (en)	2015-06-02	2016-12-08	Genentech, Inc.	Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
EP3303387A2 (de)	2015-06-05	2018-04-11	Novartis AG	Antikörper gegen knochenmorphogenetisches protein 9 (bmp9) und verfahren dafür
EP3302525A2 (de)	2015-06-05	2018-04-11	Novartis AG	Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
JP7497953B2 (ja)	2015-06-12	2024-06-11	アレクトルエルエルシー	抗ｃｄ３３抗体及びその使用方法
AU2016276981B2 (en)	2015-06-12	2022-10-06	Alector Llc	Anti-CD33 antibodies and methods of use thereof
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
UA126892C2 (uk)	2015-06-16	2023-02-22	Мерк Патент Гмбх	Спосіб лікування запущеної поширеної нирковоклітинної карциноми (arcc)
EP3310385A4 (de)	2015-06-17	2018-12-19	Allakos Inc.	Verfahren und zusammensetzungen zur behandlung von fibrotischen erkrankungen
CA2986263A1 (en)	2015-06-17	2016-12-22	Genentech, Inc.	Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
US20190194315A1 (en)	2015-06-17	2019-06-27	Novartis Ag	Antibody drug conjugates
EP3334446A4 (de)	2015-06-17	2019-06-19	International Aids Vaccine Initiative	Manipulierte äussere domäne von hv-gp120-mutanten und verwendung davon
JOP20200312A1 (ar)	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
EP3313885A1 (de)	2015-06-29	2018-05-02	H. Hoffnabb-La Roche Ag	Typ-ii-cd20-antikörper zur verwendung in der organtransplantation
US10077313B2 (en)	2015-06-29	2018-09-18	Immunogen, Inc.	Anti-CD123 antibodies and conjugates and derivatives thereof
WO2017023866A1 (en)	2015-07-31	2017-02-09	Boston Biomedical, Inc.	Method of targeting stat3 and other non-druggable proteins
JP6940479B2 (ja)	2015-08-03	2021-09-29	ノバルティスアーゲー	Ｆｇｆ２１関連障害を処置する方法
TWI797060B (zh)	2015-08-04	2023-04-01	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108137702B (zh)	2015-08-28	2023-01-06	艾利妥	抗siglec-7抗体及其使用方法
JP6861418B2 (ja)	2015-09-02	2021-04-28	イッサムリサーチデベロップメントカンパニーオブザヘブリューユニバーシティーオブエルサレムリミテッド	ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
CN108350605A (zh)	2015-09-04	2018-07-31	台湾浩鼎生技股份有限公司	聚糖阵列以及使用方法
TN2018000076A1 (en)	2015-09-09	2019-07-08	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
HUE053914T2 (hu)	2015-09-09	2021-07-28	Novartis Ag	Csecsemõmirigy-stróma eredetû limfopoietinhez (TSLP-hez) kötõdõ ellenanyagok és az ellenanyagok alkalmazására szolgáló eljárások
US10894988B2 (en)	2015-09-11	2021-01-19	The Board Of Trustees Of The Leland Stanford Junior University	Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis
US9862760B2 (en)	2015-09-16	2018-01-09	Novartis Ag	Polyomavirus neutralizing antibodies
AU2016326609B2 (en)	2015-09-23	2023-03-09	Mereo Biopharma 5, Inc.	Methods and compositions for treatment of cancer
ES2768957T3 (es)	2015-09-24	2020-06-24	Abvitro Llc	Composiciones de anticuerpos contra el VIH y métodos de uso
US10017572B2 (en)	2015-09-25	2018-07-10	Genentech, Inc.	Anti-tigit antibodies and methods of use
WO2017058881A1 (en)	2015-09-28	2017-04-06	The Trustees Of Columbia University In The City Of New York	Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US20180282415A1 (en)	2015-09-30	2018-10-04	Merck Patent Gmbh	Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
FI3359572T3 (fi)	2015-10-06	2025-01-27	Hoffmann La Roche	Menetelmä multippeliskleroosin hoitamiseksi
JP2018537956A (ja)	2015-10-06	2018-12-27	アレクトルエルエルシー	抗ｔｒｅｍ２抗体及びその使用方法
EP3362093A4 (de)	2015-10-13	2019-05-08	Technion Research & Development Foundation Limited	Heparanase-neutralisierende monoklonale antikörper
EP4273235A3 (de)	2015-10-21	2024-01-17	Redcoat Solutions, Inc.	Monoklonale antikörper gegen bettwanzen und verfahren zur herstellung und verwendungen davon
EP3370515B1 (de)	2015-10-21	2022-01-26	Redcoat Solutions, Inc.	Bettwanzenerfassungsvorrichtung
US10604577B2 (en)	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
RU2018119317A (ru)	2015-10-28	2019-12-04	Йейл Юниверсити	Гуманизированное антитело к dkk2 и его применение
WO2017075432A2 (en)	2015-10-29	2017-05-04	Alector Llc	Anti-siglec-9 antibodies and methods of use thereof
SI3374398T1 (sl)	2015-11-10	2020-07-31	Medimmune, Llc	Vezavne molekule, specifične za ASCT2 in njihove uporabe
CN106729743B (zh)	2015-11-23	2021-09-21	四川科伦博泰生物医药股份有限公司	抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
WO2017089593A1 (en)	2015-11-26	2017-06-01	Universite Paris Descartes	Inhibitors for treating or preventing a pulmonary arterial hypertension in systemic sclerosis patients and method for diagnosing said disease
MY186414A (en)	2015-12-15	2021-07-22	Gilead Sciences Inc	Human immunodeficiency virus neutralizing antibodies
CN108368180B (zh)	2015-12-17	2022-07-26	詹森药业有限公司	喹硫平的抗体及其用途
EP3390449A1 (de)	2015-12-17	2018-10-24	Janssen Pharmaceutica N.V.	Antikörper gegen risperidon und verwendung davon
TW201731872A (zh)	2015-12-18	2017-09-16	諾華公司	標靶CD32b之抗體及其使用方法
JP6954842B2 (ja)	2015-12-25	2021-10-27	中外製薬株式会社	増強された活性を有する抗体及びその改変方法
WO2017115773A1 (ja)	2015-12-28	2017-07-06	中外製薬株式会社	Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
JP7046814B2 (ja)	2015-12-30	2022-04-04	ジェネンテック，インコーポレイテッド	タンパク質製剤のためのトリプトファン誘導体の使用
EP3397287A1 (de)	2015-12-30	2018-11-07	Genentech, Inc.	Formulierungen mit reduziertem abbau von polysorbat
AR107303A1 (es)	2016-01-08	2018-04-18	Hoffmann La Roche	Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
WO2017122130A1 (en)	2016-01-11	2017-07-20	Novartis Ag	Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
WO2017125897A1 (en)	2016-01-21	2017-07-27	Novartis Ag	Multispecific molecules targeting cll-1
EP3408671B1 (de)	2016-01-25	2023-11-01	F. Hoffmann-La Roche AG	Verfahren zum testen t-zell-abhängiger bispezifischer antikörper
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
US20190048071A1 (en)	2016-02-19	2019-02-14	Morphosys Ag	Antibodies for il-17c
US11066456B2 (en)	2016-02-25	2021-07-20	Washington University	Compositions comprising TREM2 and methods of use thereof
JP6966176B2 (ja)	2016-03-01	2021-11-10	イサムリサーチディベロップメントカンパニーオブザヘブルーユニバーシティオブエルサレムエルティーディー．	ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体
AU2017226955B2 (en)	2016-03-04	2023-03-16	Morphosys Ag	Polypeptide library
JP7023853B2 (ja)	2016-03-04	2022-02-22	アレクトルエルエルシー	抗ｔｒｅｍ１抗体及びその使用方法
EP3216458A1 (de)	2016-03-07	2017-09-13	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
EP3426693A4 (de)	2016-03-08	2019-11-13	Academia Sinica	Verfahren zur modularen synthese von n-glykanen und anordnungen davon
EP4465045A3 (de)	2016-03-10	2025-02-26	Acceleron Pharma Inc.	Activin-typ-2-rezeptorbindende proteine und verwendungen davon
CA3016552A1 (en)	2016-03-15	2017-09-21	Genentech, Inc.	Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
WO2017161206A1 (en)	2016-03-16	2017-09-21	Halozyme, Inc.	Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
AU2017236063B2 (en)	2016-03-23	2024-06-13	Prothix Bv	Monoclonal antibodies against the active site of factor XI and uses thereof
CA3018382A1 (en)	2016-03-29	2017-10-05	University Of Southern California	Chimeric antigen receptors targeting cancer
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
CN109311995A (zh)	2016-03-29	2019-02-05	台湾浩鼎生技股份有限公司	抗体、药物组合物和方法
AU2017240233B2 (en)	2016-03-31	2022-07-14	University Of Southern California	A highly sensitive and specific luciferase based reporter assay for antigen detection
TWI697333B (zh)	2016-04-22	2020-07-01	台灣浩鼎生技股份有限公司	經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
CN116217731A (zh)	2016-04-22	2023-06-06	艾科赛扬制药股份有限公司	Alk7结合蛋白及其用途
US10875919B2 (en)	2016-04-26	2020-12-29	Alector Llc	Chimeric receptors and methods of use thereof
WO2017189724A1 (en)	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
EP3452492A1 (de)	2016-05-05	2019-03-13	Novartis AG	Amatoxinderivate und konjugate davon als inhibitoren der rna-polymerase
KR20180137517A (ko)	2016-05-13	2018-12-27	바이오아트라, 엘엘씨	항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
MX2018014047A (es)	2016-05-17	2019-06-20	Genentech Inc	Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
MX2018014435A (es)	2016-05-26	2019-04-15	Merck Patent Gmbh	Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
SI3464318T1 (sl)	2016-06-02	2021-07-30	Abbvie Inc.	Agonist glukokortikoidnega receptorja in njegovi imunokonjugati
US10851159B2 (en)	2016-06-02	2020-12-01	Bloom Diagnostics Ag	Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
CA3027651A1 (en)	2016-06-15	2017-12-21	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
PL3472177T3 (pl)	2016-06-17	2024-11-25	F. Hoffmann-La Roche Ag	Oczyszczanie przeciwciał wieloswoistych
LT3263715T (lt)	2016-06-28	2020-06-25	Hifibio	Pavienių ląstelių transkriptomo analizės būdas
EP3263706A1 (de)	2016-06-28	2018-01-03	Centre National De La Recherche Scientifique (Cnrs)	Auf snat7 abzielende wirkstoffe zur behandlung von erkrankungen im zusammenhang mit der zellstoffwechselumprogrammierung
WO2018011691A1 (en)	2016-07-12	2018-01-18	Nestec S.A.	Competitive immunoassay methods
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
JP2019527690A (ja)	2016-07-27	2019-10-03	オービーアイファーマ，インコーポレイテッド	免疫原性／治療用グリカン組成物およびその使用
EP3491022A1 (de)	2016-07-29	2019-06-05	Institut National de la Sante et de la Recherche Medicale (INSERM)	Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
JP7121724B2 (ja)	2016-07-29	2022-08-18	オービーアイファーマ，インコーポレイテッド	ヒト抗体、医薬組成物及び方法
AR109279A1 (es)	2016-08-03	2018-11-14	Achaogen Inc	Anticuerpos anti plazomicina y métodos de uso de los mismos
WO2018027204A1 (en)	2016-08-05	2018-02-08	Genentech, Inc.	Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN118108847A (zh)	2016-08-07	2024-05-31	诺华股份有限公司	mRNA介导的免疫方法
WO2018029124A1 (en)	2016-08-08	2018-02-15	F. Hoffmann-La Roche Ag	Therapeutic and diagnostic methods for cancer
EP3497440A1 (de)	2016-08-15	2019-06-19	H. Hoffnabb-La Roche Ag	Chromatographieverfahren zur quantifizierung eines nichtionischen tensids in einer zusammensetzung mit dem nichtionischen tensid und einem polypeptid
KR102369014B1 (ko)	2016-08-16	2022-03-02	리제너론 파아마슈티컬스, 인크.	혼합물로부터 개별 항체들을 정량하는 방법
TWI764917B (zh)	2016-08-22	2022-05-21	醣基生醫股份有限公司	抗體、結合片段及使用方法
KR102579047B1 (ko)	2016-08-31	2023-09-14	온코세라피 사이언스 가부시키가이샤	MELK에 대한 단클론 항체(monoclonal antibody) 및 그 사용
WO2018045210A1 (en)	2016-09-02	2018-03-08	Therapeutics Lp 180	Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
US20190202907A1 (en)	2016-09-02	2019-07-04	180 Therapeutics Lp	Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
CA3035327A1 (en)	2016-09-06	2018-03-15	Chugai Seiyaku Kabushiki Kaisha	Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
WO2018049083A1 (en)	2016-09-07	2018-03-15	The Regents Of The University Of California	Antibodies to oxidation-specific epitopes
WO2018049261A1 (en)	2016-09-09	2018-03-15	Icellhealth Consulting Llc	Oncolytic virus expressing immune checkpoint modulators
CA3037144A1 (en)	2016-09-16	2018-03-22	Shanghai Henlius Biotech, Inc.	Anti-pd-1 antibodies
JOP20190009A1 (ar)	2016-09-21	2019-01-27	Alx Oncology Inc	أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US20190225701A1 (en)	2016-09-26	2019-07-25	The Brigham And Women's Hospital, Inc.	Regulators of b cell-mediated immunosuppression
CA3039451A1 (en)	2016-10-06	2018-04-12	Pfizer Inc.	Dosing regimen of avelumab for the treatment of cancer
TWI762516B (zh)	2016-10-06	2022-05-01	日商腫瘤療法科學股份有限公司	針對ｆｚｄ１０之單株抗體及其用途
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
CN108738313B (zh)	2016-10-20	2022-12-30	天境生物科技(上海)有限公司	新的cd47单克隆抗体及其应用
JP7102401B2 (ja)	2016-10-25	2022-07-19	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	クロマトグラフィーデータ解析のための方法およびシステム
WO2018081531A2 (en)	2016-10-28	2018-05-03	Ariad Pharmaceuticals, Inc.	Methods for human t-cell activation
US11078298B2 (en)	2016-10-28	2021-08-03	Banyan Biomarkers, Inc.	Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
WO2018083606A1 (en)	2016-11-01	2018-05-11	Novartis Ag	Methods and compositions for enhancing gene editing
WO2018087720A1 (en)	2016-11-14	2018-05-17	Novartis Ag	Compositions, methods, and therapeutic uses related to fusogenic protein minion
WO2018093465A1 (en)	2016-11-21	2018-05-24	Eirion Therapeutics, Inc.	Transdermal delivery of large agents
WO2018094414A1 (en)	2016-11-21	2018-05-24	Obi Pharma, Inc.	Conjugated biological molecules, pharmaceutical compositions and methods
EP3544601B1 (de)	2016-11-23	2024-03-20	Translational Drug Development, LLC	Eine zusammensetzung, die ein benzamid und einen tnfrsf-agonisten umfasst, der an 4-1bb oder gitr bindet, und die verwendung derselben bei der behandlung von krebs.
AU2017363309A1 (en)	2016-11-23	2019-07-11	Bioverativ Therapeutics Inc.	Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
US10852271B2 (en)	2016-12-14	2020-12-01	Taiwan Semiconductor Manufacturing Co., Ltd.	On-chip heater
IL267340B2 (en)	2016-12-15	2023-12-01	Nat Inst Biotechnology Negev Ltd	Monoclonal antibodies against PCNA and their use
EP3555120A1 (de) *	2016-12-19	2019-10-23	Abcam Plc	Monovalente und divalente bindungsproteine
JOP20190155A1 (ar)	2016-12-21	2019-06-23	Novartis Ag	مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
KR102702288B1 (ko)	2016-12-23	2024-09-05	노파르티스 아게	항-인자 XI/XIa 항체를 사용한 치료 방법
JP7139332B2 (ja)	2016-12-23	2022-09-20	ノバルティスアーゲー	第ｘｉ因子抗体および使用方法
JOP20190187A1 (ar)	2017-02-03	2019-08-01	Novartis Ag	مترافقات عقار جسم مضاد لـ ccr7
KR102572663B1 (ko)	2017-02-08	2023-09-01	노파르티스 아게	Fgf21 모방 항체 및 이의 용도
CN110546265A (zh)	2017-02-09	2019-12-06	因达普塔治疗公司	工程化自然杀伤(nk)细胞及其组合物和方法
UA126574C2 (uk)	2017-02-10	2022-11-02	Дженентек, Інк.	Антитіло проти триптази, його композиція та застосування
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
CN108456251A (zh)	2017-02-21	2018-08-28	上海君实生物医药科技股份有限公司	抗pd-l1抗体及其应用
CN110392697A (zh)	2017-03-02	2019-10-29	国家医疗保健研究所	对nectin-4具有特异性的抗体及其用途
EP3375889B1 (de)	2017-03-17	2019-12-11	HiFiBiO SAS	Einzelzellenanalyse
WO2018175924A1 (en)	2017-03-24	2018-09-27	The Broad Institute, Inc.	Methods and compositions for regulating innate lymphoid cell inflammatory responses
BR112019019939A2 (pt)	2017-03-30	2020-04-28	Merck Patent Gmbh	combinação de anticorpo anti-pd-l1 e um inibidor de dna-pk para tratamento de câncer
US20190048055A1 (en)	2017-03-31	2019-02-14	Altor Bioscience Corporation	Alt-803 in combination with anti-cd38 antibody for cancer therapies
JP7209298B2 (ja)	2017-03-31	2023-01-20	公立大学法人奈良県立医科大学	血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
US11913075B2 (en)	2017-04-01	2024-02-27	The Broad Institute, Inc.	Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018185618A1 (en)	2017-04-03	2018-10-11	Novartis Ag	Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018187074A1 (en)	2017-04-03	2018-10-11	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
RU2665790C1 (ru)	2017-04-17	2018-09-04	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело к pd-l1
US11236151B2 (en)	2017-04-25	2022-02-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
SG11201909395TA (en)	2017-04-27	2019-11-28	Tesaro Inc	Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AU2018261891B2 (en)	2017-05-05	2024-11-21	Memorial Sloan Kettering Cancer Center	Modular self assembly disassembly (SADA) technologies
CA3062415A1 (en)	2017-05-05	2018-11-08	Christopher Robert Bebbington	Methods and compositions for treating allergic ocular diseases
WO2018213316A1 (en)	2017-05-16	2018-11-22	Alector Llc	Anti-siglec-5 antibodies and methods of use thereof
EP3624846B1 (de)	2017-05-16	2024-08-07	Bhami's Research Laboratory, Pvt. Ltd.	Hochkonzentrierte proteinformulierungen mit reduzierter viskosität beinhaltend eine mischung von nicotinicsäure and tryoptophan
US11897953B2 (en)	2017-06-14	2024-02-13	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018229706A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Combination therapy for the treatment of cancer
CA3064798A1 (en)	2017-06-22	2018-12-27	Morphosys Ag	Canine antibody libraries
EP3645567A1 (de)	2017-06-27	2020-05-06	Dana-Farber Cancer Institute, Inc.	Zusammensetzungen und verfahren zur identifizierung und behandlung von resistenz gegen ctla4-antagonisten bei leukämie
WO2019000223A1 (en)	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN111094334A (zh)	2017-07-19	2020-05-01	美国卫生与公众服务部	用于诊断和治疗乙肝病毒感染的抗体和方法
WO2019018729A1 (en)	2017-07-20	2019-01-24	Dana-Farber Cancer Institute, Inc.	COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
US11174322B2 (en)	2017-07-24	2021-11-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies and peptides to treat HCMV related diseases
WO2019020807A1 (en)	2017-07-28	2019-01-31	Gene Signal International Sa	CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
WO2019023525A1 (en)	2017-07-28	2019-01-31	Dana-Farber Cancer Institute, Inc.	ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
CA3057447A1 (en)	2017-08-03	2019-02-07	Alector Llc	Anti-cd33 antibodies and methods of use thereof
MX2019012868A (es)	2017-08-03	2019-11-28	Alector Llc	Anticuerpos anti-trem2 y metodos para utilizarlos.
JP2020530297A (ja)	2017-08-11	2020-10-22	ジェネンテック，インコーポレイテッド	抗ｃｄ８抗体及びその使用
EP3668898B1 (de)	2017-08-14	2023-07-05	MorphoSys AG	Humanisierte antikörper für cd3
JP7604226B2 (ja)	2017-09-05	2024-12-23	イミュノジェン，インコーポレイテッド	患者の試料中のヒト葉酸受容体１を検出するための方法
JP7281774B2 (ja)	2017-09-19	2023-05-26	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	抗ｈｌａ－ａ２抗体及びその使用方法
MX2020002850A (es)	2017-09-19	2020-07-24	Regeneron Pharma	Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas.
JP7317023B2 (ja)	2017-09-20	2023-07-28	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	新規抗ｈｌａ－ａ２抗体、およびその使用
EP3684413A1 (de)	2017-09-20	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Dosierungsschema für kombinationstherapie unter verwendung von pd-1-achse-bindenden antagonisten und gegen gpc3 gerichteten wirkstoff
WO2019057982A1 (en)	2017-09-25	2019-03-28	Morphosys Ag	TREATMENT OF ATOPIC DERMATITIS
US11897917B2 (en)	2017-09-27	2024-02-13	The University Of York	Bioconjugation of polypeptides
US12043870B2 (en)	2017-10-02	2024-07-23	The Broad Institute, Inc.	Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EA039662B1 (ru)	2017-10-03	2022-02-24	Закрытое Акционерное Общество "Биокад"	Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru)	2017-10-03	2019-08-21	Закрытое Акционерное Общество "Биокад"	МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US12077588B2 (en)	2017-10-10	2024-09-03	Numab Therapeutics AG	Antibodies targeting PDL1 and methods of use thereof
EP3470428A1 (de)	2017-10-10	2019-04-17	Numab Innovation AG	Anti cd137 antikörper und deren verwendung
EP3470429A1 (de)	2017-10-10	2019-04-17	Numab Innovation AG	Auf pdl1 gerichtete antikörper und verfahren zur verwendung davon
CA3075337A1 (en)	2017-10-10	2019-04-18	Numab Therapeutics AG	Antibodies targeting cd137 and methods of use thereof
US11753458B2 (en)	2017-10-10	2023-09-12	Alpine Immune Sciences, Inc.	CTLA-4 variant immunomodulatory proteins and uses thereof
CA3185107A1 (en)	2017-10-12	2019-04-18	Immunowake Inc.	Vegfr-antibody light chain fusion protein
WO2019079362A1 (en)	2017-10-16	2019-04-25	Massachusetts Institute Of Technology	HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
EP3700933A1 (de)	2017-10-25	2020-09-02	Novartis AG	Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
PE20210553A1 (es) *	2017-11-01	2021-03-17	Chugai Pharmaceutical Co Ltd	Variantes e isoformas de anticuerpos con actividad biologica reducida
JP2021503891A (ja)	2017-11-22	2021-02-15	ノバルティスアーゲー	抗第ＸＩ／ＸＩａ因子抗体に対する反転結合剤およびそれらの使用
WO2019102456A1 (en)	2017-11-27	2019-05-31	University Of Rijeka Faculty Of Medicine	Immunotoxins for treating cancer
US11433132B2 (en)	2017-12-01	2022-09-06	Novartis Ag	Polyomavirus neutralizing antibodies
WO2019113506A1 (en)	2017-12-07	2019-06-13	The Broad Institute, Inc.	Methods and compositions for multiplexing single cell and single nuclei sequencing
CA3085472A1 (en)	2017-12-19	2019-06-27	The Rockefeller University	Human igg fc domain variants with improved effector function
CN111491951B (zh) *	2017-12-22	2024-05-24	豪夫迈·罗氏有限公司	通过疏水相互作用色谱法耗尽轻链错配的抗体变体
WO2019129221A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against tigit
US12168688B2 (en)	2017-12-28	2024-12-17	Nanjing Legend Biotech Co., Ltd.	Antibodies and variants thereof against PD-L1
US11440957B2 (en)	2017-12-29	2022-09-13	Alector Llc	Anti-TMEM106B antibodies and methods of use thereof
BR112020013236A2 (pt)	2018-01-03	2020-12-01	Alpine Immune Sciences, Inc.	proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
JP7366908B2 (ja)	2018-01-15	2023-10-23	ナンジンレジェンドバイオテックカンパニー，リミテッド	Ｐｄ－１に対する単一ドメイン抗体及びその変異体
JP7268038B2 (ja)	2018-01-31	2023-05-02	アレクトルエルエルシー	抗ｍｓ４ａ４ａ抗体及びその使用方法
KR102417088B1 (ko)	2018-02-09	2022-07-07	제넨테크, 인크.	비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
KR20200135331A (ko)	2018-02-14	2020-12-02	비엘라 바이오, 인크.	고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
EP3759141A1 (de)	2018-02-26	2021-01-06	F. Hoffmann-La Roche AG	Dosierung zur behandlung mit anti-tigit- und anti-pd-l1--antagonist-antikörpern
GB201803563D0 (en)	2018-03-06	2018-04-18	Galapagos Nv	Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
CN112292401A (zh)	2018-03-06	2021-01-29	英凯尔生物科技有限责任公司	丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
RU2020128013A (ru)	2018-03-14	2022-04-15	Бейцзин Сюаньи Фармасайенсиз Ко., Лтд.	Антитела против клаудина 18.2
EP3765517A1 (de)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
JP2021517152A (ja)	2018-03-15	2021-07-15	ビオンドバイオロジクスリミテッド	可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物
RU2020134294A (ru)	2018-03-21	2022-04-22	ЭйЭлЭкс Онколоджи Инк.	Антитела против сигнал-регуляторного белка альфа и способы их применения
TW202003567A (zh)	2018-03-30	2020-01-16	大陸商南京傳奇生物科技有限公司	針對lag-3之單一結構域抗體及其用途
WO2019195181A1 (en)	2018-04-05	2019-10-10	Gilead Sciences, Inc.	Antibodies and fragments thereof that bind hepatitis b virus protein x
KR20210003147A (ko)	2018-04-13	2021-01-11	제넨테크, 인크.	안정된 항-cd79b 면역접합체 제제
WO2019201904A1 (en)	2018-04-16	2019-10-24	Merck Patent Gmbh	Viscosity reduction of highly concentrated protein formulations
US11957695B2 (en)	2018-04-26	2024-04-16	The Broad Institute, Inc.	Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US12084489B2 (en)	2018-05-02	2024-09-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
WO2019211489A1 (en)	2018-05-04	2019-11-07	Merck Patent Gmbh	COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER
WO2019213660A2 (en)	2018-05-04	2019-11-07	The Broad Institute, Inc.	Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
AU2019264965A1 (en)	2018-05-09	2020-11-19	Nectin Therapeutics Ltd.	Antibodies specific to human Nectin4
AU2019271146A1 (en)	2018-05-14	2020-12-10	Indapta Therapeutics, Inc.	Subsets of human natural killer cells with enhanced antibody-directed immune responses
WO2019222294A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
EP3794024B1 (de)	2018-05-14	2023-05-10	Werewolf Therapeutics, Inc.	Aktivierbare interleukin-2-polypeptide und verfahren zu ihrer verwendung
AU2019270342A1 (en)	2018-05-16	2020-10-29	Morphosys Ag	Antibodies targeting glycoprotein VI
CA3099917A1 (en)	2018-05-24	2019-11-28	Ares Trading S.A.	Method for controlling the afucosylation level of a glycoprotein composition
AU2019272885A1 (en)	2018-05-25	2020-11-26	Alector Llc	Anti-SIRPA antibodies and methods of use thereof
BR112020023380A2 (pt)	2018-05-31	2021-02-09	Glyconex Inc.	anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo isolado, vetor recombinante, célula hospedeira, método para produzir um anticorpo ou um fragmento de aglutinação ao antígeno do mesmo e para tratar ou detectar câncer, conjugado de anticorpo ,e, composição farmacêutica
CN112165974B (zh)	2018-05-31	2024-11-08	诺华股份有限公司	乙型肝炎抗体
WO2019232542A2 (en)	2018-06-01	2019-12-05	Massachusetts Institute Of Technology	Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US11492409B2 (en)	2018-06-01	2022-11-08	Novartis Ag	Binding molecules against BCMA and uses thereof
WO2019236965A1 (en)	2018-06-08	2019-12-12	Alector Llc	Anti-siglec-7 antibodies and methods of use thereof
US12036240B2 (en)	2018-06-14	2024-07-16	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
AR115571A1 (es)	2018-06-20	2021-02-03	Novartis Ag	Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
KR20210024550A (ko)	2018-06-23	2021-03-05	제넨테크, 인크.	Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
US11203645B2 (en)	2018-06-27	2021-12-21	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
MX2020013324A (es)	2018-06-29	2021-05-12	Alector Llc	Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
WO2020007822A1 (en)	2018-07-02	2020-01-09	Conservatoire National Des Arts Et Metiers (Cnam)	Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
TWI853823B (zh)	2018-07-02	2024-09-01	美商里珍納龍藥品有限公司	自混合物製備多肽之系統及方法
TW202011995A (zh)	2018-07-03	2020-04-01	比利時商葛萊伯格有限公司	高濃度液體抗體配製物
KR20230065382A (ko)	2018-07-13	2023-05-11	알렉터 엘엘씨	항-소틸린 항체 및 이들의 사용 방법
US20200171146A1 (en)	2018-07-18	2020-06-04	Genentech, Inc.	Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020023920A1 (en)	2018-07-27	2020-01-30	Alector Llc	Anti-siglec-5 antibodies and methods of use thereof
SG11202100601TA (en)	2018-08-08	2021-02-25	Genentech Inc	Use of tryptophan derivatives and l-methionine for protein formulation
WO2020041541A2 (en)	2018-08-23	2020-02-27	Seattle Genetics, Inc.	Anti-tigit antibodies
CA3108808A1 (en)	2018-08-31	2020-03-05	Alector Llc	Anti-cd33 antibodies and methods of use thereof
WO2020053122A1 (en)	2018-09-10	2020-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination of her2/neu antibody with heme for treating cancer
WO2020053742A2 (en)	2018-09-10	2020-03-19	Novartis Ag	Anti-hla-hbv peptide antibodies
EP3850013A4 (de)	2018-09-10	2022-10-05	Nanjing Legend Biotech Co., Ltd.	Einzeldomänenantikörper gegen cll1 und verwendungen davon
MX2021003213A (es)	2018-09-21	2021-05-12	Genentech Inc	Metodos de diagnostico para cancer de mama triple negativo.
AU2019346012A1 (en)	2018-09-26	2021-04-15	Merck Patent Gmbh	Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
BR112021005907A2 (pt)	2018-09-27	2021-08-10	Xilio Development, Inc.	citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
TWI839395B (zh)	2018-10-09	2024-04-21	瑞士商Ｎｕｍａｂ治療公司	靶向cd137的抗體及其使用方法
EP3636320A1 (de)	2018-10-09	2020-04-15	Numab Therapeutics AG	Auf cd137 gerichtete antikörper und verfahren zur verwendung davon
CN113329769A (zh)	2018-10-11	2021-08-31	斯克里普斯研究学院	具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
US20220411783A1 (en)	2018-10-12	2022-12-29	The Broad Institute, Inc.	Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
JP2022505041A (ja)	2018-10-15	2022-01-14	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	Ｄｎａアルキル化剤及びａｔｒ阻害剤を使用する併用療法
WO2020081730A2 (en)	2018-10-16	2020-04-23	Massachusetts Institute Of Technology	Methods and compositions for modulating microenvironment
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
WO2020092937A1 (en)	2018-11-02	2020-05-07	Annexon, Inc.	Compositions and methods for treating brain injury
JP7620546B2 (ja)	2018-11-05	2025-01-23	ジェネンテック，インコーポレイテッド	原核宿主細胞における２鎖タンパク質の産生方法
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
GB201818618D0 (en)	2018-11-15	2019-01-02	Amlo Biosciences Ltd	Monoclonal antibodies against ambra-1
GB201818622D0 (en)	2018-11-15	2019-01-02	Amlo Biosciences Ltd	Monoclonal antibodies against loricrin
WO2020107002A2 (en)	2018-11-21	2020-05-28	Indapta Therapeutics, Inc.	Methods for expansion of natural killer (nk) cell subset and related compositions and methods
SG11202104838SA (en)	2018-12-03	2021-06-29	Eirion Therapeutics Inc	Improved delivery of large agents
WO2020115115A1 (en)	2018-12-05	2020-06-11	Morphosys Ag	Multispecific antigen-binding molecules
CA3121565A1 (en)	2018-12-07	2020-06-11	Jiangsu Hengrui Medicine Co., Ltd.	Cd3 antibody and pharmaceutical use thereof
JP7608334B2 (ja)	2018-12-14	2025-01-06	モルフォシス・アーゲー	抗体製剤
KR20210132644A (ko)	2018-12-18	2021-11-04	캐터펄트 테라퓨틱스 비.브이.	이식편 대 숙주 질환(GvHD)의 예방 또는 치료를 위한 항-CCR7 mAb의 용도
TW202039586A (zh)	2018-12-18	2020-11-01	瑞士商諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
TW202039554A (zh)	2018-12-19	2020-11-01	瑞士商諾華公司	抗ＴＮＦ－α抗體
AU2019410643A1 (en)	2018-12-21	2021-08-12	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
EP3898984A1 (de)	2018-12-21	2021-10-27	Genentech, Inc.	Verfahren zur herstellung von polypeptiden unter verwendung einer gegen apoptose resistenten zelllinie
JP7607564B2 (ja)	2018-12-21	2024-12-27	ノバルティスアーゲー	Ｐｍｅｌ１７に対する抗体及びその結合体
EP3902823A1 (de)	2018-12-24	2021-11-03	Sanofi	Multispezifische bindungsproteine mit mutanten fab-domänen
SG11202106668WA (en)	2018-12-26	2021-07-29	Hope City	Activatable masked anti-ctla4 binding proteins
KR102713267B1 (ko)	2018-12-28	2024-10-04	스팍스 테라퓨틱스 인크.	암 및 다른 질환을 치료하기 위한 클라우딘 18.2에 특이적인 결합 분자, 이의 조성물 및 방법
US11739156B2 (en)	2019-01-06	2023-08-29	The Broad Institute, Inc. Massachusetts Institute of Technology	Methods and compositions for overcoming immunosuppression
AU2020207664A1 (en)	2019-01-13	2021-07-22	University Of Rijeka Faculty Of Medicine	Antibodies specific to human Nectin-2
CN113710702A (zh)	2019-01-14	2021-11-26	健泰科生物技术公司	用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
EP3689907A1 (de)	2019-01-31	2020-08-05	Numab Therapeutics AG	Auf il-17a gerichtete antikörper und verfahren zur verwendung davon
MA54857A (fr)	2019-01-31	2021-12-08	Numab Therapeutics AG	Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
MX2021010313A (es)	2019-02-27	2021-09-23	Genentech Inc	Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
PE20220495A1 (es)	2019-03-01	2022-04-07	Allogene Therapeutics Inc	Receptores antigenicos quimericos y agentes de union dirigidos a dll3
US20230012428A1 (en)	2019-03-06	2023-01-12	Jiangsu Hengrui Medicine Co., Ltd.	Bifunctional fusion protein and pharmaceutical use thereof
US20220154282A1 (en)	2019-03-12	2022-05-19	The Broad Institute, Inc.	Detection means, compositions and methods for modulating synovial sarcoma cells
CA3132771A1 (en)	2019-03-14	2020-09-17	Morphosys Ag	Antibodies targeting c5ar
US20220143148A1 (en)	2019-03-14	2022-05-12	The Broad Institute, Inc.	Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
BR112021018205A2 (pt)	2019-03-14	2021-12-28	Biond Biologics Ltd	Pequenos agentes bloqueadores de liberação.
CN113574071A (zh)	2019-03-15	2021-10-29	莫佛塞斯公司	用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
US20220152148A1 (en)	2019-03-18	2022-05-19	The Broad Institute, Inc.	Modulation of type 2 immunity by targeting clec-2 signaling
US20220185875A1 (en)	2019-03-18	2022-06-16	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific antibody specifically bound to vegf and ang2
EP3942023A1 (de)	2019-03-18	2022-01-26	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
EP3947446A1 (de)	2019-03-25	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
JP7589168B2 (ja)	2019-04-01	2024-11-25	ジェネンテック，インコーポレイテッド	タンパク質含有製剤を安定化するための組成物および方法
EP3955925A4 (de)	2019-04-18	2023-03-22	QLSF Biotherapeutics Inc.	Humanisierte anti-pd-l1-antikörper
EP3956664A1 (de)	2019-04-18	2022-02-23	Genentech, Inc.	Antikörperpotenztest
BR112021019571A2 (pt)	2019-04-19	2021-12-07	Chugai Pharmaceutical Co Ltd	Receptor quimérico que reconhece o sítio de modificação do anticorpo
RU2734432C1 (ru)	2019-04-23	2020-10-16	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с GITR
GB201906302D0 (en)	2019-05-03	2019-06-19	Amlo Biosciences Ltd	Methods of determining the margin of a tumour
MX2021013222A (es)	2019-05-03	2022-01-06	Genentech Inc	Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
GB201906297D0 (en)	2019-05-03	2019-06-19	Amlo Biosciences Ltd	Biomarkers for disease progression in squamous cell carcinoma
JP2022532519A (ja)	2019-05-03	2022-07-15	モルフォシス・アーゲー	限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
SG11202112382WA (en)	2019-05-07	2021-12-30	Gracell Biotechnologies Shanghai Co Ltd	Engineered immune cell targeting bcma and use thereof
EP3969038A1 (de)	2019-05-14	2022-03-23	Eirion Therapeutics, Inc.	Verzögerung der spitzenwirkung und/oder verlängerung der dauer der reaktion
WO2020232305A1 (en)	2019-05-14	2020-11-19	Werewolf Therapeutics, Inc.	Separation moieties and methods and use thereof
EP3821250B1 (de)	2019-05-16	2022-05-04	ProciseDx Inc.	Testverfahren zum nachweis von vcam-1 und alpha-2-makroglobulin in blut
EP3969906A1 (de)	2019-05-16	2022-03-23	ProciseDx Inc.	Assay-nachweisverfahren für vcam-1 und calprotectin
CA3138360A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Cd19 binding molecules and uses thereof
WO2020236797A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Variant cd58 domains and uses thereof
JP2022537887A (ja)	2019-05-21	2022-08-31	ノバルティスアーゲー	Ｂｃｍａに対する三重特異性結合分子及びその使用
WO2020236528A1 (en)	2019-05-23	2020-11-26	Procisedx Inc.	Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
WO2020243661A1 (en)	2019-05-31	2020-12-03	The Broad Institute, Inc.	Methods for treating metabolic disorders by targeting adcy5
US12066432B2 (en)	2019-06-05	2024-08-20	Gynuity Health Projects, Inc.	Placental protein biomarkers for gestational age assessment and related methods
AR119264A1 (es)	2019-06-05	2021-12-09	Genentech Inc	Método para reutilización de cromatografía
JP2022535125A (ja)	2019-06-06	2022-08-04	プロサイセデクスインコーポレイティド	血中ヘモグロビンＡ１Ｃ（ＨｂＡ１ｃ）の検出
CA3140023A1 (en)	2019-06-11	2020-12-17	Alector Llc	Anti-sortilin antibodies for use in therapy
KR20220019785A (ko)	2019-06-12	2022-02-17	노파르티스 아게	나트륨이뇨 펩티드 수용체 1 항체 및 사용 방법
KR20220024729A (ko)	2019-06-24	2022-03-03	노파르티스 아게	B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
EP3990922A1 (de)	2019-06-25	2022-05-04	ProciseDx Inc.	Nachweis von anti-tnf-alpha biologika und anti-wirkstoff-antikörpern
WO2020264300A1 (en)	2019-06-28	2020-12-30	Genentech, Inc.	Composition and methods for stabilizing liquid protein formulations
CA3145301A1 (en)	2019-07-08	2021-01-14	Imcare Biotech, Llc.	Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
WO2021005232A1 (en)	2019-07-11	2021-01-14	Umc Utrecht Holding B.V.	Intranasal administration of neutralising antiviral antibodies
US20220267452A1 (en)	2019-07-12	2022-08-25	Chugai Seiyaku Kabushiki Kaisha	Anti-mutation type fgfr3 antibody and use therefor
PH12022550141A1 (en)	2019-07-19	2023-12-04	Oncoresponse Inc	Immunomodulatory antibodies and methods of use thereof
WO2021016598A1 (en)	2019-07-25	2021-01-28	Immunowake Inc.	Methods of measuring cell-mediated killing by effectors
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
WO2021022083A2 (en)	2019-07-31	2021-02-04	Alector Llc	Anti-ms4a4a antibodies and methods of use thereof
GB201911210D0 (en)	2019-08-06	2019-09-18	Amlo Biosciences Ltd	Clinical management of oropharyngeal squamous cell carcinoma
AU2020328931A1 (en)	2019-08-12	2022-03-24	Biond Biologics Ltd.	Antibodies against ILT2 and use thereof
US20220282333A1 (en)	2019-08-13	2022-09-08	The General Hospital Corporation	Methods for predicting outcomes of checkpoint inhibition and treatment thereof
AU2020341458A1 (en)	2019-09-04	2022-04-21	Genentech, Inc.	CD8 binding agents and uses thereof
EP4028523A1 (de)	2019-09-09	2022-07-20	Scribe Therapeutics Inc.	Zusammensetzungen und verfahren zur verwendung in der immuntherapie
US12235262B1 (en)	2019-09-09	2025-02-25	10X Genomics, Inc.	Methods and systems for single cell protein analysis
US20240043512A1 (en)	2019-09-11	2024-02-08	Imcare Biotech, Llc	Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
TW202118512A (zh)	2019-09-12	2021-05-16	美商建南德克公司	治療狼瘡性腎炎之組成物及方法
EP4031106A1 (de)	2019-09-17	2022-07-27	Merck Patent GmbH	Camphersulfonsäure und kombinationen davon mit kationischen hilfsstoffen als viskositätsreduzierende mittel in hochkonzentrierten proteinformulierungen
KR20220066295A (ko)	2019-09-20	2022-05-24	제넨테크, 인크.	항트립타제 항체의 투약
WO2021058729A1 (en)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
MX2022003610A (es)	2019-09-27	2022-04-20	Genentech Inc	Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
JP2022550325A (ja)	2019-09-27	2022-12-01	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	抗ミュラー管抑制物質抗体およびその使用
US11981922B2 (en)	2019-10-03	2024-05-14	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en)	2019-10-03	2025-01-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
GB201914399D0 (en)	2019-10-04	2019-11-20	Univ Newcastle	Biomarkers for assessing explant organ viability
US11793787B2 (en)	2019-10-07	2023-10-24	The Broad Institute, Inc.	Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
IL292181A (en)	2019-10-31	2022-06-01	Morphosys Ag	Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
TW202131949A (zh)	2019-10-31	2021-09-01	德商莫菲西斯公司	包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
BR112022007787A2 (pt)	2019-11-01	2022-07-05	Ares Trading Sa	Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer
KR20220097443A (ko)	2019-11-05	2022-07-07	메르크 파텐트 게엠베하	암의 치료를 위한 PD-1, TGFβ 및 TIGIT의 조합 억제
KR20220092584A (ko)	2019-11-05	2022-07-01	메르크 파텐트 게엠베하	항tigit 항체 및 이의 용도
US20220389103A1 (en)	2019-11-06	2022-12-08	Genentech, Inc.	Diagnostic and therapeutic methods for treatment of hematologic cancers
JP2023503258A (ja)	2019-11-14	2023-01-27	ウェアウルフセラピューティクス，インコーポレイテッド	活性化可能サイトカインポリペプチド及びその使用方法
TWI774137B (zh)	2019-11-26	2022-08-11	大陸商上海岸邁生物科技有限公司	針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
AU2020397888A1 (en)	2019-12-05	2022-06-09	Alector Llc	Methods of use of anti-TREM2 antibodies
WO2021116789A1 (en)	2019-12-09	2021-06-17	Novartis Ag	Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
WO2021116119A1 (en)	2019-12-09	2021-06-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to her4 and uses thereof
WO2021116277A1 (en)	2019-12-10	2021-06-17	Institut Pasteur	New antibody blocking human fcgriiia and fcgriiib
JP2023506014A (ja)	2019-12-12	2023-02-14	アレクトルエルエルシー	抗ｃｄ３３抗体の使用方法
CR20220329A (es)	2019-12-13	2022-11-23	Alector Llc	Anticuerpos anti–mertk y metodos de uso de los mismos
US11865168B2 (en)	2019-12-30	2024-01-09	Massachusetts Institute Of Technology	Compositions and methods for treating bacterial infections
US12165747B2 (en)	2020-01-23	2024-12-10	The Broad Institute, Inc.	Molecular spatial mapping of metastatic tumor microenvironment
EP4096646A1 (de)	2020-01-27	2022-12-07	Genentech, Inc.	Methoden zur behandlung von krebs mit einem antitigit-antagonistischen antikörper
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021151974A1 (en)	2020-01-28	2021-08-05	Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis	Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
KR20220136378A (ko)	2020-01-31	2022-10-07	제넨테크, 인크.	Pd-1 축 결합 길항제 및 rna 백신을 이용하여 네오에피토프-특이적 t 세포를 유도하는 방법
CN113248611A (zh)	2020-02-13	2021-08-13	湖南华康恒健生物技术有限公司	抗bcma抗体、其药物组合物及应用
EP4106767A1 (de)	2020-02-21	2022-12-28	Université de Liège	Erschöpfung der ext1-expression und/oder -aktivität verbessert die zelluläre produktion von biologischen entitäten
WO2021164728A1 (zh)	2020-02-21	2021-08-26	江苏恒瑞医药股份有限公司	一种抗il-4r抗体药物组合物及其用途
WO2021173565A1 (en)	2020-02-24	2021-09-02	Alector Llc	Methods of use of anti-trem2 antibodies
WO2021176034A1 (en)	2020-03-05	2021-09-10	Umc Utrecht Holding B.V.	Membrane ubiquitin ligases to target protein degradation
WO2021255280A1 (en)	2020-06-18	2021-12-23	Umc Utrecht Holding B.V.	Screening method for effective target - e3 ligase combinations
BR112022018254A2 (pt)	2020-03-13	2022-10-25	Genentech Inc	Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
US20230128499A1 (en)	2020-03-27	2023-04-27	Novartis Ag	Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
US20240294650A1 (en)	2020-03-31	2024-09-05	Alector Llc	Anti-mertk antibodies and methods of use thereof
AU2021247286A1 (en)	2020-04-03	2022-10-20	Alector Llc	Methods of use of anti-TREM2 antibodies
AU2021253899A1 (en)	2020-04-06	2022-11-17	University Of Rijeka Faculty Of Medicine	Antibodies to NKp46 and constructs thereof for treatment of cancers and infections
JP2023521785A (ja)	2020-04-09	2023-05-25	テクニッシェウニベルシタットミュンヘン	肺線維症の治療のためのマクロファージへのｍｉＲ－２１阻害剤の標的送達
WO2021209458A1 (en)	2020-04-14	2021-10-21	Ares Trading S.A.	Combination treatment of cancer
US20230165836A1 (en)	2020-04-21	2023-06-01	Université Catholique de Louvain	Alpha-2 adrenergic receptor agonists for the treatment of cancer
WO2021214175A1 (en)	2020-04-21	2021-10-28	Université Catholique de Louvain	Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders
EP4139449A1 (de)	2020-04-22	2023-03-01	Fabmid	Verfahren zur zirkularisierung linearer doppelsträngiger nukleinsäuren
WO2021216790A1 (en)	2020-04-22	2021-10-28	Indapta Therapeutics, Inc.	Natural killer (nk) cell compositions and methods for generating same
EP4143225A4 (de)	2020-04-27	2024-05-15	The Regents of the University of California	Isoform-unabhängige antikörper gegen lipoprotein(a)
WO2021222533A1 (en)	2020-04-30	2021-11-04	Procisedx Inc.	Methods of detecting antibodies to sars-cov-2
US20230181756A1 (en)	2020-04-30	2023-06-15	Novartis Ag	Ccr7 antibody drug conjugates for treating cancer
EP4146684A2 (de)	2020-05-08	2023-03-15	Alpine Immune Sciences, Inc.	April- und baff-hemmende immunmodulatorische proteine mit und ohne t-zell-hemmendes protein und verfahren zur verwendung davon
CN115551553A (zh)	2020-05-12	2022-12-30	Inserm(法国国家健康医学研究院)	治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
GB202007312D0 (en)	2020-05-18	2020-07-01	Synthetic Vac Ltd	Mimotope peptides of the spike protein from the sars-cov-2 virus
US20230183376A1 (en)	2020-05-22	2023-06-15	Chugai Seiyaku Kabushiki Kaisha	Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
GB202008651D0 (en)	2020-06-09	2020-07-22	Univ Newcastle	Method of identifying complement modulators
AU2021293038A1 (en)	2020-06-16	2023-02-02	F. Hoffmann-La Roche Ag	Methods and compositions for treating triple-negative breast cancer
IL298946A (en)	2020-06-18	2023-02-01	Genentech Inc	Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
JP2023530499A (ja)	2020-06-22	2023-07-18	モルフォシス・アーゲー	抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
CN113912706A (zh)	2020-07-09	2022-01-11	北京凯因科技股份有限公司	结合乙型肝炎病毒表面抗原的抗体及其应用
CR20230009A (es)	2020-07-16	2023-01-25	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
CN116782902A (zh)	2020-07-23	2023-09-19	伊拉兹马斯大学鹿特丹医学中心	作为骨髓增殖性肿瘤中的新治疗靶标的s100蛋白
FR3112939B1 (fr)	2020-07-31	2024-01-05	Univ Montpellier	Produit universel de thérapie cellulaire et son utilisation
WO2022031749A1 (en)	2020-08-03	2022-02-10	Genentech, Inc.	Diagnostic and therapeutic methods for lymphoma
WO2022035793A1 (en)	2020-08-10	2022-02-17	Precision Biosciences, Inc.	Antibodies and fragments specific for b-cell maturation antigen and uses thereof
US12071479B2 (en)	2020-08-12	2024-08-27	Biond Biologics Ltd.	Antibodies against ILT2 and use thereof
WO2022044010A1 (en)	2020-08-26	2022-03-03	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
CN114106173A (zh)	2020-08-26	2022-03-01	上海泰槿生物技术有限公司	抗ox40抗体、其药物组合物及应用
FR3114160A1 (fr)	2020-09-11	2022-03-18	Dyameo	Rapporteur fluorescent et son utilisation pour la détection de molécules cibles
BR112023004415A2 (pt)	2020-09-11	2023-05-09	Medimmune Ltd	Moléculas terapêuticas de ligação a b7-h4
WO2022053685A2 (en)	2020-09-12	2022-03-17	Medimmune Limited	A scoring method for an anti-b7h4 antibody-drug conjugate therapy
JP2023542079A (ja)	2020-09-21	2023-10-05	ジェネンテック，インコーポレイテッド	多重特異性抗体の精製
EP4217003A1 (de)	2020-09-24	2023-08-02	Genentech, Inc.	Polysorbatmischungen mit modifizierter fettsäureesterverteilung
AU2021350342A1 (en)	2020-09-24	2023-03-09	Morphosys Ag	Novel human antibodies binding to human CD3 epsilon
WO2022084915A1 (en)	2020-10-22	2022-04-28	Janssen Biotech, Inc.	Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
WO2022093981A1 (en)	2020-10-28	2022-05-05	Genentech, Inc.	Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CA3196550A1 (en)	2020-11-02	2022-05-05	Yan Lan	Combination treatment of cancer
EP4237001A1 (de)	2020-11-02	2023-09-06	Ares Trading S.A.	Kombinationsbehandlung von krebs
JP2023549140A (ja)	2020-11-04	2023-11-22	マイエロイド・セラピューティクス，インコーポレーテッド	操作されたキメラ融合タンパク質組成物およびその使用方法
WO2022097090A1 (en)	2020-11-05	2022-05-12	Novartis Ag	Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
WO2022097060A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
US20240002509A1 (en)	2020-11-06	2024-01-04	Novartis Ag	ANTIBODY Fc VARIANTS
IL302412A (en)	2020-11-06	2023-06-01	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CA3200974A1 (en)	2020-11-08	2022-05-12	Seagen Inc.	Combination therapy
US11999786B2 (en)	2020-11-24	2024-06-04	Novartis Ag	Anti-CD48 antibodies, antibody drug conjugates, and uses thereof
US20240101681A1 (en)	2020-12-02	2024-03-28	Alector Llc	Methods of use of anti-sortilin antibodies
AU2021391623A1 (en)	2020-12-04	2023-06-29	Incyte Corporation	Anti-cd19 combination therapy
CA3200847A1 (en)	2020-12-07	2022-06-16	UCB Biopharma SRL	Multi-specific antibodies and antibody combinations
MX2023006649A (es)	2020-12-07	2023-06-21	UCB Biopharma SRL	Anticuerpos contra interleucina-22.
WO2022125710A1 (en)	2020-12-09	2022-06-16	GHP Solutions, LLC	Methods of detecting papp-a and related methods for gestational age assessment
EP4259661A1 (de)	2020-12-14	2023-10-18	Novartis AG	Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
WO2022140797A1 (en)	2020-12-23	2022-06-30	Immunowake Inc.	Immunocytokines and uses thereof
MX2023008485A (es)	2021-01-20	2023-07-28	Oncoresponse Inc	Anticuerpos inmunomoduladores y usos de estos.
WO2022172267A1 (en)	2021-02-11	2022-08-18	Nectin Therapeutics Ltd.	Antibodies against cd112r and uses thereof
CA3209364A1 (en)	2021-03-01	2022-09-09	Jennifer O'neil	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
TW202317612A (zh)	2021-03-01	2023-05-01	美商艾希利歐發展股份有限公司	用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
US20240141026A1 (en)	2021-03-04	2024-05-02	Centre National De La Recherche Scientifique	Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
CA3211581A1 (en)	2021-03-10	2022-09-15	Ellen WU	Immunomodulatory molecules and uses thereof
EP4454652A2 (de)	2021-03-15	2024-10-30	F. Hoffmann-La Roche AG	Zusammensetzungen und verfahren zur behandlung von lupus nephritis
MX2023010916A (es)	2021-03-17	2023-12-14	Myeloid Therapeutics Inc	Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas.
US20240174746A1 (en)	2021-03-18	2024-05-30	Alector Llc	Anti-tmem106b antibodies and methods of use thereof
CR20230488A (es)	2021-03-18	2023-12-12	Medimmune Ltd	Moléculas de unión terapéuticas
JP2024511610A (ja)	2021-03-23	2024-03-14	アレクトルエルエルシー	コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
BR112023019205A2 (pt)	2021-03-26	2023-10-24	Janssen Biotech Inc	Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos
WO2022217026A1 (en)	2021-04-09	2022-10-13	Seagen Inc.	Methods of treating cancer with anti-tigit antibodies
BR112023021475A2 (pt)	2021-04-16	2023-12-19	Novartis Ag	Conjugados anticorpo-fármaco e métodos para produzir os mesmos
EP4326288A1 (de)	2021-04-21	2024-02-28	Indapta Therapeutics, Inc.	Verfahren zur behandlung und dosierung von natürlichen killerzellzusammensetzungen
IL308163A (en)	2021-05-03	2024-01-01	Merck Patent Gmbh	Her2 targeting fc antigen binding fragment-drug conjugates
WO2022233764A1 (en)	2021-05-03	2022-11-10	UCB Biopharma SRL	Antibodies
WO2022236335A1 (en)	2021-05-07	2022-11-10	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2022241057A1 (en)	2021-05-12	2022-11-17	Applied Biomedical Science Institute	Binding polypeptides against sars cov-2 and uses thereof
WO2022242710A1 (zh)	2021-05-19	2022-11-24	上海诗健生物科技有限公司	一种特异性识别baff-r的嵌合抗原受体分子及其应用
IL308818A (en)	2021-05-25	2024-01-01	Merck Patent Gmbh	Egfr targeting fc antigen binding fragment-drug conjugates
JP2024520764A (ja)	2021-06-07	2024-05-24	アレストレーディングソシエテアノニム	癌の組み合わせ処置
WO2022266221A1 (en)	2021-06-16	2022-12-22	Alector Llc	Monovalent anti-mertk antibodies and methods of use thereof
CN117642426A (zh)	2021-06-16	2024-03-01	艾莱克特有限责任公司	双特异性抗MerTK和抗PDL1抗体及其使用方法
US20250032578A1 (en)	2021-06-18	2025-01-30	Advancecor Gmbh	Use of a pharmaceutical composition
JP2024527559A (ja)	2021-07-01	2024-07-25	インダプタセラピューティクスインコーポレイテッド	操作されたナチュラルキラー（ｎｋ）細胞及び関連する方法
CA3227537A1 (en)	2021-07-27	2023-02-02	Morphosys Ag	Combinations of antigen binding molecules
IL310437A (en)	2021-07-29	2024-03-01	Inst Nat Sante Rech Med	Humanized anti-human βig-h3 protein and uses thereof
CN117897409A (zh)	2021-08-13	2024-04-16	基因泰克公司	抗类胰蛋白酶抗体的给药
WO2023044321A1 (en)	2021-09-14	2023-03-23	Xilio Development, Inc.	Cleavable linkers
WO2023064872A1 (en)	2021-10-14	2023-04-20	Precision Biosciences, Inc.	Combinations of anti-bcma car t cells and gamma secretase inhibitors
WO2023064947A1 (en)	2021-10-15	2023-04-20	Regenxbio Inc.	Antibodies and methods of using thereof
WO2023069919A1 (en)	2021-10-19	2023-04-27	Alector Llc	Anti-cd300lb antibodies and methods of use thereof
WO2023072958A1 (en)	2021-10-25	2023-05-04	Fabmid	Methods for circularizing linear double stranded nucleic acids and the products thereof
JP2024540196A (ja)	2021-10-27	2024-10-31	グラニットバイオアーゲー	Ｃｃｒ２を標的とする抗体
JP2024539994A (ja)	2021-10-27	2024-10-31	ジェネンテック，インコーポレイテッド	拘束性錯化剤の合成
WO2023081898A1 (en)	2021-11-08	2023-05-11	Alector Llc	Soluble cd33 as a biomarker for anti-cd33 efficacy
JP2024544885A (ja)	2021-11-10	2024-12-05	ジェネンテック，インコーポレイテッド	抗インターロイキン－３３抗体及びその使用
WO2023105528A1 (en)	2021-12-12	2023-06-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to ceacam1
WO2023117987A1 (en)	2021-12-21	2023-06-29	Universität Zürich	Adenoviral vectors
AU2022417501A1 (en)	2021-12-22	2024-07-04	Genentech, Inc.	Clinical formulations of anti-tigit antibodies
CN118742568A (zh)	2021-12-23	2024-10-01	布罗德研究所股份有限公司	并行抗体工程化组合物和方法
EP4475954A1 (de)	2022-02-07	2024-12-18	Yeda Research and Development Co. Ltd.	Humanisierte antikörper gegen quicosin-sefhydrye-oxidase 1 (qsox1) und verwendungen davon
TW202348252A (zh)	2022-02-16	2023-12-16	英商梅迪繆思有限公司	用治療性結合分子治療癌症的組合療法
AU2023222463A1 (en)	2022-02-18	2024-08-08	Adivo Gmbh	Feline antibody library
AU2023225020A1 (en)	2022-02-23	2024-09-12	Alector Llc	Methods of use of anti-trem2 antibodies
GB202202569D0 (en)	2022-02-24	2022-04-13	Amlo Biosciences Ltd	Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
KR20240152853A (ko)	2022-02-28	2024-10-22	실리오 디벨럽먼트, 인크.	표적화된 사이토카인 및 이의 사용 방법
WO2023164286A1 (en)	2022-02-28	2023-08-31	Xilio Development, Inc.	Engineered cd122 compositions and methods thereof
IL315308A (en)	2022-03-09	2024-10-01	Astrazeneca Ab	Binding molecules against frα
WO2023170291A1 (en)	2022-03-11	2023-09-14	Janssen Pharmaceutica Nv	Multispecific antibodies and uses thereof
KR20240156640A (ko)	2022-03-11	2024-10-30	얀센 파마슈티카 엔브이	다중특이적 항체 및 이의 용도
AU2023232448A1 (en)	2022-03-11	2024-10-24	Janssen Pharmaceutica Nv	Multispecific antibodies and uses thereof
AU2023229967A1 (en)	2022-03-11	2024-08-08	Astrazeneca Ab	A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
CN118974081A (zh)	2022-03-11	2024-11-15	国家健康与医学研究院（Inserm）	特异性重编程b细胞和t细胞的核酸系统及其用途
WO2023175171A1 (en)	2022-03-18	2023-09-21	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Bk polyomavirus antibodies and uses thereof
CN118922448A (zh)	2022-03-22	2024-11-08	莫佛塞斯公司	Cd3特异性的去免疫抗体
EP4499846A1 (de)	2022-03-25	2025-02-05	Universität Zürich	Adenovirales targeting von aktivierten immunzellen
WO2023187657A1 (en)	2022-03-30	2023-10-05	Novartis Ag	Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
KR20240165358A (ko)	2022-04-01	2024-11-22	제넨테크, 인크.	폴리펩티드를 안정화하기 위한 하이드록시프로필 메틸 셀룰로오스 유도체
IL315886A (en)	2022-04-14	2024-11-01	Novartis Ag	Dosing regimens for anti-CD19 agents and their uses
CN119487072A (zh)	2022-04-25	2025-02-18	比昂生物制剂公司	抗ilt3抗体及其用途
AR129136A1 (es)	2022-04-26	2024-07-17	Novartis Ag	Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
EP4269432A1 (de)	2022-04-26	2023-11-01	Universite de Rouen Normandie	Herstellung von therapeutischen antikörpern durch die mikroalge phaeodactylum tricornutum
IL317449A (en)	2022-06-07	2025-02-01	Genentech Inc	Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
WO2024007020A1 (en)	2022-06-30	2024-01-04	Indapta Therapeutics, Inc.	Combination of engineered natural killer (nk) cells and antibody therapy and related methods
CN119487070A (zh)	2022-07-07	2025-02-18	赛美欧治疗股份公司	靶向cd117的抗体
AU2023307223A1 (en)	2022-07-14	2025-02-20	The Broad Institute, Inc.	Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
US20240141007A1 (en)	2022-07-15	2024-05-02	Xilio Development, Inc.	Engineered cleavable carriers and methods of use thereof
WO2024026447A1 (en)	2022-07-29	2024-02-01	Alector Llc	Anti-gpnmb antibodies and methods of use thereof
WO2024038165A1 (en)	2022-08-18	2024-02-22	Immunocore Ltd	T cell receptor fusion proteins specific for mage a4
WO2024047114A1 (en)	2022-08-31	2024-03-07	Universität Zürich	Adenoviral-based in situ delivery of bispecific t cell engagers
WO2024052503A1 (en)	2022-09-08	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en)	2022-09-12	2024-03-21	Institut National de la Santé et de la Recherche Médicale	New anti-itgb8 antibodies and its uses thereof
WO2024077018A2 (en)	2022-10-04	2024-04-11	Alpine Immune Sciences, Inc.	Methods and uses of taci-fc fusion immunomodulatory protein
WO2024074649A1 (en)	2022-10-05	2024-04-11	Alcea Therapeutics, Inc.	Notch4 antibodies, compositions, and methods for treating airway inflammation
WO2024074706A1 (en)	2022-10-07	2024-04-11	Universität Zürich	Paracrine adenoviral delivery of biomolecules
WO2024077256A1 (en)	2022-10-07	2024-04-11	The General Hospital Corporation	Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024086796A1 (en)	2022-10-20	2024-04-25	Alector Llc	Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024099990A1 (en)	2022-11-07	2024-05-16	Leibniz-Institut Für Immuntherapie (Lit)	TGF-ß SWITCH RECEPTOR CAR T CELLS
TW202434286A (zh)	2022-11-08	2024-09-01	美商建南德克公司	治療兒童期發病的特發性腎病症候群之組成物及方法
WO2024100663A1 (en)	2022-11-10	2024-05-16	Famewave Ltd.	Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
WO2024108178A1 (en)	2022-11-18	2024-05-23	Genentech, Inc.	Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
TW202440623A (zh)	2022-11-28	2024-10-16	美商艾洛基因醫療公司	靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024116053A1 (en)	2022-11-28	2024-06-06	Novartis Ag	Pcta derivatives, conjugates thereof and uses thereof
US20240269203A1 (en)	2022-12-20	2024-08-15	Janssen Biotech, Inc.	Oncolytic virus and uses thereof
WO2024133890A1 (en)	2022-12-23	2024-06-27	Cimeio Therapeutics Ag	Antibodies targeting cd45
WO2024148232A2 (en)	2023-01-06	2024-07-11	Alector Llc	Anti-il18 binding protein antibodies and methods of use thereof
WO2024170660A1 (en)	2023-02-16	2024-08-22	Astrazeneca Ab	Combination therapies for treatment of cancer with therapeutic binding molecules
GB202303531D0 (en)	2023-03-10	2023-04-26	Fusion Antibodies Plc	Antibodies and uses thereof
WO2024191807A1 (en)	2023-03-10	2024-09-19	Seagen Inc.	Methods of treating cancer with anti-tigit antibodies
WO2024192141A1 (en)	2023-03-13	2024-09-19	Dana-Farber Cancer Institute, Inc.	Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024200425A1 (en)	2023-03-27	2024-10-03	Adivo Gmbh	Anti-canine pd-l1 antibodies
WO2024200846A1 (en)	2023-03-30	2024-10-03	272BIO Limited	Gnrh-binding polypeptides and uses thereof
WO2024211287A1 (en)	2023-04-03	2024-10-10	Seagen Inc.	Production cell lines with targeted integration sites
WO2024209089A1 (en)	2023-04-07	2024-10-10	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
WO2024236163A1 (en)	2023-05-17	2024-11-21	Morphosys Ag	T cell receptor beta constant region 2 (trbc2) antibodies
WO2024236167A1 (en)	2023-05-17	2024-11-21	Morphosys Ag	Il-13 receptor alpha 2 binding polypeptides
WO2024243217A1 (en)	2023-05-25	2024-11-28	BioLegend, Inc.	Ceacam6 binding antibodies and antigen-binding fragments thereof
WO2024245988A1 (en)	2023-05-29	2024-12-05	Granite Bio Ag	Antibodies targeting ccr2
WO2024246356A1 (en)	2023-06-01	2024-12-05	Pierre Fabre Medicament	Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis
WO2024254455A1 (en)	2023-06-08	2024-12-12	Genentech, Inc.	Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2024261027A1 (en)	2023-06-19	2024-12-26	Vector Biopharma Ag	Il-7-retargeting of adenoviruses for cell specific infection
WO2025003511A1 (en)	2023-06-30	2025-01-02	Morphosys Ag	Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025012417A1 (en)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025027472A2 (en)	2023-07-31	2025-02-06	Astrazeneca Ab	Cd123 antibody-drug conjugates and methods of using the same
WO2025032158A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Method to treat tauopathies
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025036892A1 (en)	2023-08-14	2025-02-20	Morphosys Ag	Cycat halfbody molecules comprising sterically occluding moieties

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4000098A (en) *	1974-08-16	1976-12-28	Palo Alto Medical Research Foundation	Separation of proteins by hydrophobic adsorption
US5618920A (en) *	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
WO1989006692A1 (en) *	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5851527A (en) *	1988-04-18	1998-12-22	Immunomedics, Inc.	Method for antibody targeting of therapeutic agents
DE3920358A1 (de) *	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5231178A (en) *	1991-01-16	1993-07-27	The Salk Institute Biotechnology/Industrial Associates, Inc.	Method for the purification of intact, correctly-folded insulin-like growth factor-1
DE4118120A1 (de) *	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US6407213B1 (en) *	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
EP0604580A1 (de) *	1991-09-19	1994-07-06	Genentech, Inc.	Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper.
AU3178993A (en) *	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
CA2150262C (en) *	1992-12-04	2008-07-08	Kaspar-Philipp Holliger	Multivalent and multispecific binding proteins, their manufacture and use
CA2117477C (en)	1992-12-11	2001-06-12	Peter S. Mezes	Multivalent single chain antibodies
GB9412166D0 (en)	1993-09-22	1994-08-10	Medical Res Council	Retargetting antibodies
US5429746A (en) *	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
US5641870A (en) *	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5747035A (en) *	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
CN1173878A (zh) *	1995-10-16	1998-02-18	尤尼利弗公司	双功能或双价抗体片段类似物

1995
- 1995-04-20 US US08/425,763 patent/US5641870A/en not_active Expired - Lifetime
1996
- 1996-04-05 EP EP06022818A patent/EP1752465B1/de not_active Expired - Lifetime
- 1996-04-05 EP EP96912575A patent/EP0821695B1/de not_active Expired - Lifetime
- 1996-04-05 AT AT06022818T patent/ATE510854T1/de active
- 1996-04-05 DK DK96912575T patent/DK0821695T3/da active
- 1996-04-05 JP JP53177496A patent/JP4042868B2/ja not_active Expired - Lifetime
- 1996-04-05 AT AT96912575T patent/ATE346858T1/de active
- 1996-04-05 CA CA002214633A patent/CA2214633C/en not_active Expired - Lifetime
- 1996-04-05 MX MX9707909A patent/MX9707909A/es unknown
- 1996-04-05 DK DK06022818.6T patent/DK1752465T3/da active
- 1996-04-05 DE DE69636733T patent/DE69636733T2/de not_active Expired - Lifetime
- 1996-04-05 AU AU55349/96A patent/AU721736B2/en not_active Expired
- 1996-04-05 ES ES06022818T patent/ES2365929T3/es not_active Expired - Lifetime
- 1996-04-05 ES ES96912575T patent/ES2277344T3/es not_active Expired - Lifetime
- 1996-04-05 WO PCT/US1996/004683 patent/WO1996033208A1/en active IP Right Grant
- 1996-04-05 NZ NZ306718A patent/NZ306718A/en not_active IP Right Cessation
- 1996-04-05 PT PT96912575T patent/PT821695E/pt unknown
- 1996-04-11 ZA ZA9602885A patent/ZA962885B/xx unknown
- 1996-04-17 IL IL11794296A patent/IL117942A/xx not_active IP Right Cessation
1997
- 1997-03-06 US US08/811,757 patent/US6066719A/en not_active Expired - Lifetime
1999
- 1999-02-11 US US09/249,230 patent/US6214984B1/en not_active Expired - Lifetime
- 1999-02-16 NZ NZ334211A patent/NZ334211A/xx not_active IP Right Cessation
2001
- 2001-01-04 US US09/754,998 patent/US7038017B2/en not_active Expired - Fee Related
2005
- 2005-07-01 US US11/173,564 patent/US8012754B2/en not_active Expired - Fee Related
2006
- 2006-05-15 JP JP2006135062A patent/JP4091087B2/ja not_active Expired - Lifetime
- 2006-05-15 JP JP2006135061A patent/JP4153533B2/ja not_active Expired - Lifetime
2007
- 2007-04-25 HK HK07104405.4A patent/HK1099310A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1996033208A1 (en)	1996-10-24
US5641870A (en)	1997-06-24
US20050271654A1 (en)	2005-12-08
MX9707909A (es)	1997-11-29
CA2214633C (en)	2009-02-24
NZ306718A (en)	1999-04-29
NZ334211A (en)	2000-09-29
EP1752465A3 (de)	2008-02-27
EP0821695A1 (de)	1998-02-04
US8012754B2 (en)	2011-09-06
US7038017B2 (en)	2006-05-02
HK1099310A1 (en)	2007-08-10
AU721736B2 (en)	2000-07-13
ES2365929T3 (es)	2011-10-13
US6214984B1 (en)	2001-04-10
US6066719A (en)	2000-05-23
ZA962885B (en)	1997-10-13
CA2214633A1 (en)	1996-10-24
PT821695E (pt)	2007-03-30
JP2006257098A (ja)	2006-09-28
JPH11504007A (ja)	1999-04-06
ATE510854T1 (de)	2011-06-15
IL117942A0 (en)	1996-08-04
AU5534996A (en)	1996-11-07
JP4042868B2 (ja)	2008-02-06
JP2006262906A (ja)	2006-10-05
US20020002271A1 (en)	2002-01-03
JP4153533B2 (ja)	2008-09-24
DE69636733T2 (de)	2007-10-18
ES2277344T3 (es)	2007-07-01
DK0821695T3 (da)	2007-03-26
EP1752465B1 (de)	2011-05-25
EP1752465A2 (de)	2007-02-14
JP4091087B2 (ja)	2008-05-28
DK1752465T3 (da)	2011-08-15
DE69636733D1 (de)	2007-01-11
EP0821695B1 (de)	2006-11-29
IL117942A (en)	2000-06-01

Publication	Publication Date	Title
ATE346858T1 (de)	2006-12-15	Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph
ES2177632T3 (es)	2002-12-16	Purificacion de anticuerpos.
PT733069E (pt)	2006-07-31	Antigenios ctla-8 de primata purificados e reagentes relacionados
FI970301A (fi)	1997-03-24	Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia
BR9507594B8 (pt)	2015-06-02	Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
DE59209129D1 (de)	1998-02-19	Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
DE69133179D1 (de)	2003-01-30	Katalytische antikörperkomponente
ES2052077T3 (es)	1994-07-01	Un sistema de expresion para la produccion de anticuerpos monoclonales quimericos.
DE59208982D1 (de)	1997-11-27	Verfahren zur Reinigung von IgG-monoklonalen Antikörpern
ATE177758T1 (de)	1999-04-15	Synthetische peptide, antikörper dagegen und ihre verwendung
BG60017B2 (bg)	1993-06-30	Метод за намаляване хетерогенността на моноклонални антитела
ES2114547T3 (es)	1998-06-01	Anticuerpos monoclonales contra el virus de la hepatitis c.
DE69635715D1 (de)	2006-03-30	Monoklonaler antikoerper spezifisch fuer prostaglandin d synthetase
ATE50458T1 (de)	1990-03-15	Bestimmung von fibrin mit fibrin-spezifischen antikoerpern.
ATE137864T1 (de)	1996-05-15	Immunobestimmung von menschlichem osteocalcin, reagenz und satz dafür
ES2061973T3 (es)	1994-12-16	Anticuerpos monoclonales que reconocen la region n-terminal de polipeptido natriuretico auricular, su preparacion y uso.
DE69333683D1 (de)	2004-12-09	Antikörper-testbesteck zur bestimmung von amylin
ATE193021T1 (de)	2000-06-15	Lipoprotein (a)-peptide und deren verwendung
ITMI932667A1 (it)	1995-06-17	Metodo per la produzione di anticorpi monoclonali specifici per le chemochine
FI940684A (fi)	1994-07-30	Menetelmä Streptococcus suis -bakteerin adhesiiniproteiinin ja sen vasta-aineen valmistamiseksi

Legal Events

Date	Code	Title	Description
2007-06-15	UEP	Publication of translation of european patent specification	Ref document number: 0821695 Country of ref document: EP

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 0821695

Country of ref document: EP